Name,CAS,Vdss (l/kg),fu,CLt,CLh,CLr,F,Fa,Fg,Fh,Therapeutic Area,Reference
Acarbose,56180-94-0,0.32,,2.2,0.1,2.1,0.01,0.01,1.01,0.99,Gastrointestinal/Metabolism,"Ahr, H. J.; Boberg, M.; Krause, H. P.; Maul, W.; Mueller, F. O.; Ploschke, H. J.; Weber, H.; Wuensche, C.  Pharmacokinetics of acarbose. Part I. Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man.    Arzneimittel-Forschung  (1989),  39(10),  1254-60.  "
Acebutolol,37517-30-9,1.7,0.74,10,7.3,2.7,0.50,0.90,0.82,0.68,Cardiovascular,"Kaye CM, Kumana CR, Leighton M, Hamer J, and Turner P (1976) Observations on the pharmacokinetics of acebutolol.  Clin. Pharmacol. Ther.  19: 416-420.  Meffin PJ, Winkle RA, Peters FA, and Harrison DC (1977) Acebutolol disposition after intravenous administration.  Clin. Pharmacol. Ther. 22: 557-567.  Roux A, Flouvat B, Chau NP, Letac B, and Lucsko M (1980) Pharmacokinetics of acebutalol after intravenous bolus administration.  Br. J. Clin. Pharmacol. 9: 215-217."
Acetaminophen,103-90-2,1,0.52,5,4.9,0.2,0.82,1.00,1.04,0.79,nervous system,"Rowlins MD, Henderson DB, Hijab AR (1977) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 11: 283-286.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467."
Acyclovir,59277-89-3,0.71,0.85,4.7,1.1,3.6,0.23,0.23,1.05,0.95,Infection,De Miranda P and Blum MR (1983) Pharmacokinetics of acyclovir after intravenous and oral administration.  J. Antimic. Chemother. 12(Suppl B): 29-37. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci. 2008 
Adefovir,106941-25-7,0.42,0.96,3.7,0.4,3.3,0.12,0.16,0.76,0.98,Infection,"Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, and Jaffe HS. (1995) Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.  Antimic. Ag. Chemother. 39: 2401-2405.   Hepsera Product Label."
Adinazolam,37115-32-5,0.98,0.31,6.2,3.6,2.6,0.39,1.00,0.46,0.84,nervous system,"Fleishaker JC, Friedman H, and Pollock SR (1991)  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.  Pharm. Res.  8: 162-167."
Alfentanil,71195-58-9,0.45,0.086,3.9,3.9,0.0,0.43,1.00,0.52,0.83,nervous system,"Bower S and Hull CJ (1982) Comparative pharmacokinetics of fentanyl and alfentanil.  Br. J. Anaesth. 54: 871-877.  McDonnell CG, Malkan D, Van Pelt FD, and Shorten GD (2003) Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.    Eur. J. Anaesth. 20: 662-667.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.    Arch. Int. Pharmacodyn. Ther.  257: 4-19.  Lemmens HJ, Burm AG, Bovill JG, Hennis PJ, and Gladines MP (1992)  Pharmacodynamics of alfentanil. The role of plasma protein binding.    Anesthesiol.  76: 65-70. Clin Pharmacol Ther. 2004 Nov;76(5):452-66. "
Alizapride,59338-93-1,1.6,,6.6,1.3,5.3,0.75,1.00,0.79,0.94,nervous system,"Houin G, Barre J, and Tillement JP (1984) Absolute intramuscular, oral, and rectal bioavailability of alizapride.  J. Pharm. Sci. 73: 1450-1453."
Allopurinol,000315-30-0,0.58,0.97,11,9.3,1.7,0.53,0.90,0.99,0.60,Others,"Breithaupt H and Tittel M (1982) Kinetics of allopurinol after sinlge intravenous and oral doses.  Eur. J. Clin. Pharmacol. 22: 77-84.  Elion GB, Kovensky A, Hitchings GH, Metz E, and Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.    Biochem. Pharmacol. 15: 863-889."
Alprazolam,28981-97-7,0.8,0.29,0.74,0.6,0.1,0.88,0.92,0.98,0.97,nervous system,"Smith RB, Kroboth PD, Vanderligt JT, Phillips JP, and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.  Psychopharmacology 84: 452-456.  Greenblatt DJ and Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications.    Clin. pharmacokinet. 24: 453-471.  "
Alprenolol,13655-52-2,3.2,0.18,15,14.4,0.6,0.08,0.93,0.23,0.37,Cardiovascular,"Bodin NO, Borg KO, Johansson R, Obianwu H, Svensson R (1974) The absorption, distribution, and excretion of alprenolol in man, dog, and rat.  Acta Pharmacol. Toxicol. 35: 261-269.   Imamura H, Komori T, Ismail A, Suenaga A, and Otagiri M (2002)  Stereoselective protein binding of alprenolol in the renal diseased state.  Chirality 14: 599-603."
Amantadine,768-94-5,6.6,0.33,4.8,0.0,4.8,0.90,0.95,0.95,1.00,Infection,Aoki FY and Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride.  Clin. Pharmacokinet. 14: 35-51.
Amiodarone ,1951-25-3,60,0.0002,1.9,1.9,0.0,0.65,1.00,0.71,0.92,Cardiovascular,"Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe DL, Zimmerman JJ, and Chow MSS (1996) Disposition of intravenous amiodarone in subjects with normal and impaired renal function.  J. Clin. Pharmacol. 36: 122-130.  Veronese ME, McLean S, and Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.  Br. J. Clin. Pharmacol 26: 721-731.  Clin Pharmacol Ther. 1985 Feb;37(2):118-23."
Amisulpride,71675-85-9,5.8,0.84,7.8,3.4,4.4,0.48,1.00,0.56,0.85,nervous system,"Coukell, Allan J.; Spencer, Caroline M.; Benfield, Paul.  Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia.    CNS Drugs  (1996),  6(3),  237-256. SOLIAN® TABLETS and SOLUTION product information"
Amitriptyline,50-48-6,8.7,0.07,6.1,6.0,0.1,0.48,0.95,0.68,0.74,nervous system,Jorgensen A and Hansen V (1976) Pharmacokinetics of amitriptyline infused intravenously in man.  Eur. J. Clin. Pharmacol.  10: 337-341.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.    Naunyn-Sch Arch. Pharmacol. 327: 260-265.
Amlodipine,88150-42-9,17,0.005,7,6.3,0.7,0.64,0.95,0.93,0.73,Cardiovascular,"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, and Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22: 21-25.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  "
Amoxicillin,26787-78-0,0.25,0.85,3.3,1.4,1.9,0.77,0.93,0.88,0.94,Infection,"Antimicrob Agents Chemother. 1980 Feb;17(2):199-202. Arancibia A, Guttmann J, Gonzalez G, and Gonzalez C (1980) Absorption and disposition kinetics of amoxicillin in normal human subjects.  Antimic. Ag. Chemother. 17: 199-202.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98."
Amphotericin B,1397-89-3,,0.04,0.46,0.4,0.0,0.05,0.05,1.02,0.98,Infection,"Morgan D J; Ching M S; Raymond K; Bury R W; Mashford M L; Kong B; Sabto J; Gurr F W; Somogyi A A  Elimination of amphotericin B in impaired renal function.    Clinical pharmacology and therapeutics  (1983),  34(2),  248-53. Rev Infect Dis 1990 12: 308-329. "
Ampicillin,69-53-4,0.22,0.85,2.8,1.6,1.2,0.62,0.65,1.03,0.93,Infection,"Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.    Antimic. Ag. Chemother. 33: 1470-1476.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98."
Antipyrine,000060-80-0,0.77,0.93,0.64,0.6,0.0,0.97,0.97,1.03,0.97,nervous system,"Danhof, M.; Van Zuilen, A.; Boeijinga, J. K.; Breimer, D. D.  Studies of the different metabolic pathways of antipyrine in man.  Oral versus i.v. administration and the influence of urinary collection time.    European Journal of Clinical Pharmacology  (1982),  21(5),  433-41. Andreasen PB and Vesell ES (1974) Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.  Clin. Pharmacol. Ther. 16: 1059-1065.    Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003)  Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021."
Atenolol,29122-68-7,0.95,0.94,2.5,0.0,2.5,0.50,0.50,1.00,1.00,Cardiovascular,"Mason WD, Winer N, Kochak G, Cohen I, and Bell R (1979) Kinetics and absolute bioavailability of atenolol.  Clin. Pharmacol. Ther.  25: 408-415.  Henry JA and Mitchell SN (1981)  Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. "
Atomoxetine,83015-26-3,0.85,0.02,9.3,9.0,0.3,0.63,1.00,1.04,0.61,nervous system,Strattera Product Label
Atovaquone,95233-18-4,0.6,0.001,0.15,0.2,0.0,0.06,0.06,1.01,0.99,Infection,Mepron Product Label
Atropine,51-55-8,3.3,0.61,7.6,3.3,4.3,0.50,0.98,0.59,0.86,nervous system,"Hinderling, Peter H.; Gundert-Remy, Ursula; Schmidlin, Olga.  Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans.  I:  Pharmacokinetics.    Journal of Pharmaceutical Sciences  (1985),  74(7),  703-10. Adams RG, Verma P, Jackson AJ, and Miller RL (1982) Plasma pharmacokinetics of intravenously administered atropine in normal human subjects.  J. Clin. Pharmacol. 22: 477-481.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467."
Azithromycin,83905-01-5,33,0.88,10,9.6,0.5,0.34,0.60,0.97,0.58,Infection,"Clin Pharmacokinet 1993 25:370-374. Shiba, Kohya; Yoshida, Masaki; Sakai, Osamu; Shindo, Nahoko; Imai, Takeo; Isida, Yuichiro; Matsumoto, Fumio; Saiko, Yasushi; Saito, Isao; et al.  Pharmacokinetics of azithromycin in patients with renal failure.    Nippon Kagaku Ryoho Gakkai Zasshi  (1995),  43(Suppl. 6),  186-92. Luke DR, Foulds G, Cohen SF, and Levy B (1996) Safety, toleration, and pharmacokinetics of intravenous azithromycin.  Antimic. Ag. Chemother.  40: 2577-2581.  Foulds G, Shepard RM, and Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues.  J. Antimic. Chemother. 25(Suppl. A):  73-82."
Aztreonam,78110-38-0,0.18,0.4,1.5,0.5,1.0,0.01,0.01,1.02,0.98,Infection,"Creasey, William A.; Adamovics, John; Dhruv, Rohini; Platt, Thomas B.; Sugerman, A. Arthur.  Pharmacokinetic interaction of aztreonam with other antibiotics.    Journal of Clinical Pharmacology  (1984),  24(4),  174-80. Burgess DS, Summers KK, and HardinTC (1999) Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.  Clin. Ther. 21: 1882-1889.  Swabb EA, Sugerman A, Frantz M, Platt TB, and Stern M (1983) Renal handling of the monobactam azthreonam in healthy subjects.  Clin. Pharmacol. Ther. 33: 609-614."
Betaxolol,63659-18-7,4.8,0.4,3.4,2.7,0.7,0.89,1.00,1.01,0.88,Cardiovascular,"Ludden TM, Boyle DA, Gieseker D, Kennedy GT, Crawford MH, Ludden LK, and Clementi WA (1988) Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.  J. Pharm. Sci. 77: 779-783.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. "
Biperiden,514-65-8,12,0.097,12,12.0,0.0,0.33,1.00,0.69,0.48,nervous system,"Grimaldi R, Perucca E, Ruberto G, Gelmi C, Trimarchi F, Hollmann M, and Crema A (1986) Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.  Eur. J. Clin. Pharmacol.  29: 735-737.  Nakashima E, Yokogawa K, Ichimura F, Kurata K, Kido H, Yamaguchi N, and Yamana T (1987) A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans.  Chem. Pharm. Bull. 35: 718-725."
Bisoprolol,66722-44-9,2.4,0.66,3.7,1.4,2.3,0.85,0.95,0.95,0.94,Cardiovascular,"Leopold, G.  Balanced pharmacokinetics and metabolism of bisoprolol.    Journal of Cardiovascular Pharmacology  (1986),  8(Suppl. 11),  S16-S20. Le Jeunne C; Poirier J M; Cheymol G; Ertzbischoff O; Engel F; Hugues F C  Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.    European journal of clinical pharmacology  (1991),  41(2),  171-4. Horikiri Y, Suzuki T, and Mizobe M (1998) Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans.  J. Pharm. Sci. 87: 289-294.  Leopold G, Pabst J, Ungethuem W, and Buehring KU (1986) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist.  J. Clin. Pharmacol. 26: 616-621.  "
Bromazepam,1812-30-2,0.85,0.48,0.51,0.3,0.3,0.84,0.84,1.01,0.99,nervous system,"Sawada, Hideo; Hara, Akira; Yano, Hiroko; Kido, Akira.  Blood level and urinary excretion of bromazepam in man.    Gifu Daigaku Igakubu Kiyo  (1973),  21(4),  248-59. Raaflaub VJ and Speiser-Courvoisier J (1974) Zur pharmakokinetik von bromazepam beim menschen.  Arz. Forsch. 24: 1841-1844.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12: 612-619."
Bromfenac,91714-94-2,0.11,0.11,1.3,1.3,0.0,0.67,1.00,0.71,0.94,nervous system,"Gumbhir-Shah K, Cevallos WH, DeCleene SA, Halstenson CE, and Korth-Bradley JM (1997) Absolute bioavailability of bromfenac in humans.  Ann. Pharmacother. 31: 395-399."
Budesonide,51333-22-3,3.9,0.13,20,19.0,1.0,0.11,1.00,0.63,0.17,Respiratory and inflammation,"Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, and Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.  Eur. J. Resp. Dis. 63: 86-95.  Entocort EC Product Label."
Buflomedil,55837-25-7,1.3,0.4,5.6,4.3,1.3,0.75,1.00,0.92,0.81,Cardiovascular,"Gundert-Remy U, Weber E, Lam G, Chiou WL, Mann W, and Aynilian GH (1981) The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration.  Eur. J.Clin. Pharmacol. 20: 459-63.  Rey E, D'Athis P, Richard MO, Fillastre JP, and Olive G (1984) Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.  Int. J. Clin. Pharmacol. Ther. Toxicol. 12: 648-652."
Bufuralol,54340-62-4,1.7,0.19,8.9,8.9,0.0,0.43,1.00,0.70,0.61,Cardiovascular,"Dayer P, Balant L, Kupfer A, Striberni R, and Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.  Eur. J. Clin. Pharmacol. 28: 317-320.  Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding.  Drug Metab. Dispos. 32: 295-304."
Bumetanide,28395-03-1,0.16,0.031,2.5,1.0,1.5,0.70,0.90,0.82,0.96,Cardiovascular,"Marshall, James D.; Wells, Thomas G.; Letzig, Lynda; Kearns, Gregory L.  Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients.    Journal of Clinical Pharmacology  (1998),  38(11),  994-1002 Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, and Penttila A (1985) Bumetanide kinetics in renal failure.  Clin. Pharmacol. Ther. 37:  582-528.  Lau HSH, Hyneck ML, Berardi RR, Swartz RD, and Smith DE (1986) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.  Clin. Pharmacol. Ther. 39: 635-645.  Cook JA, Smith DE, Cornish LA, Tankanow RM, Nicklas JM, and Hyneck ML (1988) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.  Clin. Pharmacol. Ther. 44: 487-500."
Bupivacaine,2180-92-9,0.84,0.056,4.3,4.2,0.1,0.00,0.90,0.00,0.82,nervous system,"Berggren, Sofia; Hoogstraate, Janet; Fagerholm, Urban; Lennernas, Hans.  Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.    European Journal of Pharmaceutical Sciences  (2004),  21(4),  553-560. Burm AGL, Van der Meer AD, Van Kleef JW, Zeijlmans PWM, and Groen K (1994) Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate.  Br. J. Clin. Pharmacol. 38: 125-129."
Busulphan,55-98-1,0.55,1,2.4,2.4,0.0,0.70,0.94,0.83,0.90,Cancer,"Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringden O, Eber S, Seger R, and Ljungman P (2002) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.  Bone Marrow Transplantation  30: 833-841.  Ehrsson H and Hassan M (1984) Binding of busulfan to plasma proteins and blood cells.  J. Pharm. Pharmacol.   36: 694-696."
Caffeine,58-08-2,0.63,0.64,1.4,1.4,0.0,0.98,1.00,1.04,0.94,nervous system,"Busto U; Bendayan R; Sellers E M  Clinical pharmacokinetics of non-opiate abused drugs.    Clinical pharmacokinetics  (1989),  16(1),  1-26. Blanchard J and Sawers SJA (1983) Comparative pharmacokinetics of caffeine in young and elderly men.  J. Pharmacokinet. Biopharm. 11: 109-126."
Captopril,62571-86-2,0.75,0.73,12,0.0,12.0,0.62,0.84,0.74,1.00,Cardiovascular," Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DM (1982)  Captopril kinetics. Clin. Pharmacol. Ther. 31: 452-458.  Creasy WA, Morrison RA, Singhvi SM, and Willard DA (1988) Pharmacokinetics of intravenous captopril in healthy men.  Eur. J. Clin. Pharmacol. 35: 367-370."
Carboplatin,41575-94-4,0.26,1,1.5,0.3,1.2,0.77,0.77,1.02,0.99,Cancer,"van der Vijgh W J  Clinical pharmacokinetics of carboplatin.    Clinical pharmacokinetics  (1991),  21(4),  242-61. Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, and Pinedo HM (1987) Pharmacokinetics of carboplatin after i.v. administration.    Cancer Treatment Rep.  71: 1231-1237.  Gaver RC, George AM, and Deeb G (1987) In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.  Cancer Chemother. Pharmacol. 20: 271-276."
Carvedilol,72956-09-3,1.3,0.02,7.8,7.7,0.1,0.25,0.65,0.58,0.67,Cardiovascular,"Neugebauer G, Akpan W, Mollendorff E, Neubert P, and Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans.  J. Cardiovasc. Pharmacol. 10(Suppl 11): S85-S88.   Coreg Product Label."
Cefadroxil,50370-12-2,0.23,0.39,2.5,0.2,2.3,0.95,1.00,0.96,0.99,Infection,"La Rosa F; Ripa S; Prenna M; Ghezzi A; Pfeffer M  Pharmacokinetics of cefadroxil after oral administration in humans.    Antimicrobial agents and chemotherapy  (1982),  21(2),  320-2. Marino EL, Dominguez-Gil A, and Muriel C (1982) Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil.  Int. J. Clin. Pharmacol. Ther. Toxicol. 20: 73-77.   Aratani H, Kono S, Tateishi H, Negita S, and Yamanaka Y (1980) Pharmacological studies on cefadroxil.  II.  Pharmacokinetics.  Chemotherapy 28(Suppl. 2): 75-82. "
Cefatrizine,51627-14-6,0.22,0.4,3.3,0.7,2.6,0.75,0.76,1.02,0.97,Infection,"Pfeffer M, Gaver RC, and Ximenez J (1983) Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicr. Ag. Chemother. 24: 915-920. Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98."
Cefazolin,25953-19-9,0.12,0.18,0.89,0.1,0.8,0.90,1.00,0.90,1.00,Infection,"Chanson P, Joly V, Contrepois A, Garaud JJ, Bauchet J, Mohler J, Nguyen PC, and Carbon C (1987) Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans.  Antimic. Agents Chemother. 31: 645-637.  Decroix MO, Zini R, Chaumeil JC, and Tillement JP (1988) Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs.  Biochem. Pharmacol. 37: 2807-2814.  Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404."
Cefcanel,41952-52-7,0.13,,2.6,0.2,2.4,0.40,0.42,0.96,0.99,Infection,"Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallen K, and Yisak W (1993) Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects.  Drug Metab. Dispos.  21: 171-177. "
Cefepime,88040-23-7,0.28,0.78,2.2,0.6,1.6,0.80,0.96,0.85,0.98,Infection,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, and Martin RR (1992) Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Ag. Chemother. 36: 552-557"
Cefetamet,65052-63-3,0.28,0.78,1.9,0.4,1.5,0.47,0.52,0.92,0.98,Infection,"Hayton, William L.; Kneer, Johannes; Blouin, Robert A.; Stoeckel, Klaus.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.    Antimicrobial Agents and Chemotherapy  (1990),  34(7),  1318-22 Koup JR, Dubach UC, Brandt R, Wyss R, and Stoeckel K (1988) Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.  Antimic. Ag. Chemother. 32: 573-579. "
Cefixime,79350-37-1,0.24,0.31,1,0.6,0.4,0.47,0.50,0.96,0.97,Infection,"Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, and Silber BM (1988) Absolute bioavailability of cefixime in man.  J. Clin. Pharmacol. 28: 700-706. "
Ceftriaxone,073384-59-5,0.085,0.052,0.26,0.1,0.1,0.00,0.01,1.00,0.99,Infection,"Arvidsson, Annie; Alvan, Gunnar; Angelin, Bo; Borgaa, Olof; Nord, Carl Erik.  Ceftriaxone:  renal and biliary excretion and effect on the colon microflora.    Journal of Antimicrobial Chemotherapy  (1982),  10(3),  207-15. McNamara PJ, Gibaldi M, and Stoekel K (1983) Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding II.  Physiological significance.  Eur. J. Clin. Pharmacol. 25: 407-412.  Martin C, Ragni J, Lokiec F, Guillen JC, Auge A, Pecking M, and Gouin F (1992) Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery.  Antimic. Agents Chemother.  36: 2804-2807."
Cefuroxime,55268-75-2,0.15,0.36,2.2,0.1,2.1,0.44,0.44,1.00,1.00,Infection,"Gower PE and Dash CH (1977) The pharmacokinetics of cefuroxime after intravenous injection.  Eur. J. Clin. Pharmacol. 12: 221-227.  Benson JM, Boudinot FD, Pennell AT, Cunningham FE, and DiPiro JT (1993) In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.  Antimic. Agents Chemother. 37: 1343-1347."
Cephalexin,15686-71-2,0.21,0.85,3.9,0.4,3.5,0.90,1.00,0.91,0.98,Infection,Kirby WMM and De Maine JB (1971) Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.  Postgrad. Med. J. Suppl. 47(Cephalosporin Antibiotics):  41-46.
Cephradine,38821-53-3,0.21,0.95,3.3,0.2,3.1,1.00,1.00,1.01,0.99,Infection,"Creasey, William A.; Adamovics, John; Dhruv, Rohini; Platt, Thomas B.; Sugerman, A. Arthur.  Pharmacokinetic interaction of aztreonam with other antibiotics.    Journal of Clinical Pharmacology  (1984),  24(4),  174-80. Henness, D. M.; Richards, D.; Santella, P. J.; Rubinfeld, J.  Oral bioavailability of cefadroxil, a new semisynthetic cephalosporin.    Clinical Therapeutics  (1978),  1(4),  263-73. Rattie ES, Bernardo PD, and Ravin LJ (1976) Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans.  Antimic. Ag. Chemother.  10: 283-287.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98."
Cerivastatin,145599-86-6,0.33,0.01,2.9,2.9,0.0,0.60,1.00,0.69,0.87,Cardiovascular,"Muck, Wolfgang.  Clinical pharmacokinetics of cerivastatin.    Clinical Pharmacokinetics  (2000),  39(2),  99-116. Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. 35: 255-260.  Baycol Product Label."
Chlorambucil,305-03-3,0.26,0.01,2.8,2.8,0.0,0.91,1.00,1.03,0.88,Cancer,"Newell DR, Calvert AH, Harrap KR, and McElwain TJ (1983) Studies on the pharmacokinetics of chlorambucil and prednimustine in man.  Br. J. Clin. Pharmacol. 15: 253-258.   Leukeran Product Label."
Chloramphenicol,56-75-7,0.94,0.34,2.4,2.2,0.2,0.80,0.90,0.98,0.91,Infection,"Narang APS, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease.  Eur. J. Clin. Pharmacol. 20: 479-483.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467."
Chlordiazepoxide,58-25-3,0.25,0.056,0.37,0.4,0.0,0.01,0.01,1.02,0.98,nervous system," Boxenbaum HG, Geitner KA, Dixon WR, Spiegel HE, Symington J, Christian R, Moore JD, Weissman L, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes. J. Pharmacokinet. Biopharm. 5: 3-23. Desmond PV, Patwardhan RV, Schenker S, and Hoyumpa AM (1980) Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man.  Eur. J. Clin. Pharmacol. 18: 275-278.  Desmond PV, Roberts, RK, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.    Br. J. Clin. Pharmacol.  9: 171-175.  "
Chloroquine,54-05-7,140,0.43,4.1,1.8,2.3,0.80,1.00,0.87,0.92,Infection,"White NJ (1985) Clinical pharmacokinetics of antimalaria drugs.  Clin. Pharmacokinet.  10: 187-215.  Aderounmu AF, Salako LA, Lindstroem B, Walker O, and Ekman L (1986) Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans.  Br. J. Clin. Pharmacol. 22: 559-564."
Chlorpheniramine,132-22-9,3.3,0.7,2.5,2.1,0.4,0.41,0.94,0.48,0.91,nervous system,"Huang SM, Athanikar NK, Sridhar K, Huang YC, and Chiou WL (1982) Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults.  Eur. J. Clin. Pharmacol. 22: 359-365.  Hiep BT, Gimenez F, Khanh V, Hung NK, Thuillier A, Farinotti R, and Fernandez C (1999) Binding of chlorpheniramine enantiomers to human plasma proteins.  Chirality 11: 501-504."
Chlorpromazine,50-53-3,10,0.056,16,15.8,0.2,0.32,1.00,1.03,0.31,nervous system,"Yeung PKF, Hubbard JW, Korchinski ED, and Midha KK (1993)  Pharmacokinetics of chlorpromazine and key metabolites.  Eur. J. Clin.Pharmacol. 45: 563-569.  Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Curry SH (1970) Plasma protein binding of chlorpromazine.  J. Pharm. Pharmacol. 22: 193-197."
Chlorpropamide,94-20-2,0.19,0.03,0.045,0.0,0.0,0.90,1.00,0.90,1.00,Gastrointestinal/Metabolism,Huupponen R and Lammintausta R (1981) Chlorpropamide bioavailability and pharmacokinetics.  Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 331-333.
Chlorthalidone,77-36-1,3.9,0.24,1.5,0.5,1.0,0.64,0.82,0.80,0.98,Cardiovascular,"Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, and von Rossum JM (1979) Absolute bioavailability of chlorthalidone in man: a cross over study after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 15: 35-50.  Dieterle W, Wagner J, and Faigle JW (1976)  Binding of chlorthalidone (Hygroton) to blood components in man.  Eur. J. Clin. Pharmacol. 10: 37-42."
Cibenzoline,53267-01-9 ,4.1,0.5,8.6,4.4,4.2,0.83,1.00,1.03,0.81,Cardiovascular,"Cifenline. Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, Brazzell R, and Massarella J (1991) Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J. Clin. Pharmacol. 31: 38-44.  Reidenberg MM, Lorenzo BJ, Drayer DE, Kluger J, Nestor T, Regnier JC, Kowal BA, and Bekersky I (1988) A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline.  Ther. Drug Monit. 10: 434-437."
Cidofovir,113852-37-2,0.49,1,2.5,0.3,2.3,0.05,0.05,1.01,0.99,Infection,"Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJM, and Jaffe HS (1995) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.  Antimic. AgentsChemother. 39: 1274-1282."
Cilomilast,153259-65-5,0.23,0.006,0.5,0.5,0.0,1.00,1.00,1.02,0.98,Respiratory and inflammation,"Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, and Carr A (2001)  Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.  Pharmacother. 21: 653-660.  Down G, Siederer S, Lim S, and Daley-Yates P (2006) Clinical pharmacology of cilomilast.  Clin. Pharmacokinet. 45: 217-233."
Cimetidine,051481-61-9,1.2,0.78,8.1,0.2,7.9,0.68,0.68,1.01,0.99,Gastrointestinal/Metabolism,"Karyekar, Chetan S.; Eddington, Natalie D.; Briglia, Andrew; Gubbins, Paul O.; Dowling, Thomas C.  Renal interaction between itraconazole and cimetidine.    Journal of Clinical Pharmacology  (2004),  44(8),  919-927.  Arancibia A, Schindler I, Paccot E, Ruiz I, Gonzalez G, Mella F, and Thambo S (1985) Pharmacicinetique de la cimetidine apres administration d'une dose unique par voie intraveineuse rapide et d'une autre par voie orale.  Therapie  40: 87-92.  Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferreri L, Jack R, Dellinger EP, and Simonowitz D  (1985) Cimetidine clearance in the obese.  Clin. Pharmacol. Ther. 37: 425-430.  Gugler R, Muller-Liebenau B, and Somogyi A (1982) Altered disposition and availability of cimetdine in liver cirrhotic patients.  Br. J. Clin. Pharmacol. 14: 421-429.  Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, and Bernhard H (1981) Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients.  Clin. Pharmacol. Ther. 29: 737-743."
Ciprofloxacin,85721-33-1,2.1,0.7,8.3,1.4,6.9,0.69,0.75,0.98,0.94,Infection,"Allard S; Kinzig M; Boivin G; Sorgel F; LeBel M  Intravenous ciprofloxacin disposition in obesity.    Clinical pharmacology and therapeutics  (1993),  54(4),  368-73. Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet 41:  741-750.  Jaehde U, Soergel F, Reiter A, Sigl G, Naber KG, and Schunack W (1995)  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.    Clin. Pharmacol. Ther. 58: 532-541.  Lettieri JT, Rogge MC, Kaiser L, Echols RM, and Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.  Antimic. Agents Chemother. 36: 993-996.  Ljungborg B and Nilsson-Ehle I (1988) Pharmacokinetics of intravenous ciprofloxacin at three different doses.  J. Antimic. Chemother. 22: 715-720."
Citalopram,59729-33-8,12,0.2,4.3,3.8,0.5,0.80,1.00,0.96,0.83,nervous system,"Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgensen T, and Sidhu J (1998) Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.  Eur. J. Clin. Pharmacol. 54: 237-242.  Celexa Product Label."
Clarithromycin,81103-11-9,1.5,0.23,7.3,4.7,2.6,0.55,1.00,0.69,0.80,Infection,"Chu SY, Deaton R, and Cavanaugh J (1992) Absolute bioavailability of clarithromycin after oral administration in humans.  Antimic. Ag. Chemother. 36: 1147-1150.  Kuroyama M, Motohashi S, Kumano K, and Yago K (1996)  Protein binding of clarithromycin in patients with chronic renal failure.  Jap. J. Antibiotics 49: 256-263.  Davey PG (1991) The pharmacokinetics of clarithromycin and its 14-OH metabolite.  J. Hosp. Infec. 19(Suppl A): 29-37."
Clavulanic Acid,58001-44-8,0.22,0.91,3.1,1.8,1.3,0.75,0.90,0.90,0.92,Infection,"Davies BE, Boon R, Horton R, Reubi FC, and Descoeudres CE (1988) Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin. Br. J. Clin. Pharmacol. 26: 385-390.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75."
Clinafloxacin,105956-97-6,1.9,0.96,4.7,1.5,3.2,0.90,1.00,0.96,0.93,Infection,"Randinitis EJ, Brodfuehrer JI, Eiseman I, and Vassos AB (2001) Pharmacokinetics of clinafloxacin after single and multiple doses.  Antimic. Agents Chemother. 45: 2529-2535.  Wise R, Ashby JP, and Andrews JM (1988) In vitro activity of PD 127,391, an enhanced-spectrum quinoline.    Antimic. Agents Chemother.  32: 1251-1256."
Clindamycin,18323-44-9,0.79,0.06,4.5,3.9,0.6,0.87,1.00,1.05,0.83,Infection,"Creasey, William A.; Adamovics, John; Dhruv, Rohini; Platt, Thomas B.; Sugerman, A. Arthur.  Pharmacokinetic interaction of aztreonam with other antibiotics.    Journal of Clinical Pharmacology  (1984),  24(4),  174-80.Gatti G, Flaherty J, Bubp J, White J, Borin M, and Gambertoglio J (1993) Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.  Antimic. Agents Chemother. 37: 1137-1143.  Gordon RC, Regamey C, and Kirby WMM (1973)  Serum protein binding of erythromycin, lincomycin, and clindamycin. J. Pharm. Sci. 62: 1074-1077."
Clonazepam,1622-61-3,2.9,0.15,0.88,0.9,0.0,0.98,0.98,1.04,0.96,nervous system,"Crevoisier C, Delisle MC, Joseph I, and Foletti G (2003) Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers.  Eur. Neurol. 49: 173-177.  Lucek RW and Coutinho CB.  (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-19."
Cloxacillin,61-72-3,,,1.6,0.6,1.0,0.37,0.75,0.51,0.97,Infection,"Nauta, Ernst H.; Mattie, Herman.  Dicloxacillin and cloxacillin:  Pharmacokinetics in healthy and hemodialysis subjects.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (1976),  20(1),  98-108. "
Clozapine,5786-21-0,1.6,0.055,2.5,2.5,0.0,0.27,0.55,0.55,0.89,nervous system,"Cheng YF, Lundberg T, Bondesson U, Lindstrom L, and Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol. 34: 445-449.   Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.  Br. J. Clin. Pharmacol. 46: 453-459. "
Conivaptan,210101-16-9,0.76,0.01,3,3.0,0.0,0.12,1.00,0.14,0.87,Cardiovascular,Vaprisol Product Label
Cotinine,486-56-6,1.1,,0.89,0.8,0.1,0.90,0.90,1.04,0.97,nervous system,"Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, and Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 281-287.Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.  "
Cyclophosphamide,000050-18-0,0.73,0.87,1.1,1.0,0.1,0.74,0.90,0.86,0.96,Cancer,"Juma FD, Rogers HJ, and Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 8: 209-217. "
Cyclosporine,59865-13-3,3.3,0.068,7.5,7.4,0.1,0.28,0.86,0.48,0.68,Respiratory and inflammation,"Legg B, Gupta SK, Rowland M, Johnson RWG, and Solomon LR (1988) Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 451-460.  Min DI, Lee M, Ku YM, and Flanigan M (2000) Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers.  Clin. Pharmacol. Ther. 68: 478-486.   "
Dapsone,80-08-0,0.83,0.25,0.48,0.4,0.0,0.93,1.00,0.95,0.98,Infection,Pieters FAMJ and Zuidema J (1987) The absolute bioavailability of dapsone in dogs and humans.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 396-400.  Biggs JT and Levy L (1971)  Binding of dapsone and monacetyldapsone by human plasma proteins.  Proc. Soc. Exp. Biol. Med. 137: 692-695.
Desipramine,50-47-5,15,0.16,11,10.8,0.2,0.40,1.00,0.75,0.53,nervous system,"Ciraulo DA, Barnhill JG, and Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.  Clin. Pharmacol. Ther.  43: 509-518.  Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265."
Dexamethasone,50-02-2,0.94,0.32,3.3,3.2,0.1,0.80,0.90,1.03,0.86,Respiratory and inflammation,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14.  Tsuei SE, Moore RG, Ashley JJ, and McBride WG (1979) Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.  J. Pharmacokinet. Biopharm. 7: 249-264."
Dexloxiglumide,119817-90-2,0.18,0.024,3.7,3.3,0.4,0.48,0.95,0.59,0.86,Gastrointestinal/Metabolism,"Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'Amato M, Cybulski, ZR, Chasseaud LF, and Rovati LC (2003) Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.  Xenobiotica  33: 625-641."
Diazepam,439-14-5,1,0.023,0.38,0.4,0.0,1.00,1.00,1.02,0.98,nervous system,"Wijnands, W. J. A.; Trooster, J. F. G.; Teunissen, P. C.; Cats, H. A.; Vree, T. B.  Ciprofloxacin does not impair the elimination of diazepam in humans.    Drug Metabolism and Disposition  (1990),  18(6),  954-7. Klotz U, Avant GR, Hoyumpa A, Schenker S, and Wilkinson (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man.  J. Clin. Invest. 55: 347-359.  Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990) Effect of omeprazole and cimetidine on plasma diazepam levels.  Eur. J. Clin. Pharmacol. 39: 51-54.  Herman RJ and Wilkinson GR (1996) Disposition of diazepam in young and elderky subjects after acute and chronic dosing.  Br. J. Clin. Pharmacol. 42: 147-155.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12:  612-619.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson GR, and Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175."
Diazoxide,364-98-7,0.21,0.06,0.06,0.0,0.1,0.91,0.91,1.00,1.00,Cardiovascular,"Pruitt AW et al., 1974 JPET 188 248-256. Oglivie RI, Nadeau JH, and Sitar DS (1982) Diazoxide concentration-response relation in hypertension. Hypertension 4: 167-173.   Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  "
Diclofenac,15307-86-5,0.22,0.005,3.5,3.5,0.0,0.54,1.00,0.64,0.85,Respiratory and inflammation,"Davies, Neal M.; Anderson, Keith E.  Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls.    Clinical Pharmacokinetics  (1997),  33(3),  184-213.  Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration.  Eur. J. Clin. Pharmacol. 16: 405-410.  Leucuta SE, Rus V, Bolosiu H, Mocan A, Polinicencu C, and Bojita M (1996) Farmacocinetica diclofenacului sodic administrat in doza unica pe cale intravenosa si orala sub forma de solutie injectabilia experimentala.  Farmacia 43: 43-50.  Chan KKH, Vyas KH, and Brandt KD (1987) In vitro protein binding of diclofenac sodium in plasma and synovial fluid.    J. Pharm. Sci. 76: 105-108."
Dicloxacillin,3116-76-5,0.11,0.033,2,0.8,1.2,0.68,1.00,0.70,0.97,Infection,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112."
Didanosine,69655-05-6,0.77,0.95,11,4.2,6.8,0.38,0.50,0.93,0.82,Infection,"Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, and Barbhaiya RH (1991) Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.  Clin. Pharmacol. Ther. 49: 523-535.  Videx Product Label."
Digoxin,20830-75-5,4.1,0.7,1.7,0.0,1.7,0.70,0.81,0.86,1.00,Cardiovascular,"Rengelshausen, Jens; Goeggelmann, Christoph; Burhenne, Juergen; Riedel, Klaus-Dieter; Ludwig, Jochen; Weiss, Johanna; Mikus, Gerd; Walter-Sack, Ingeborg; Haefeli, Walter E.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.    British Journal of Clinical Pharmacology  (2003),  56(1),  32-38. Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, and Horgan J (1979) Digoxin in the elderly: pharmacokinetic consequences of old age.  Clin. Pharmacol. Ther. 25: 772-776.  Ohnhaus EE, Spring P, and Dettli L (1972) Protein binding of digoxin in human serum.    Eur. J. Clin. Pharmacol.  5: 34-36."
Diltiazem,33286-22-5,4.1,0.18,13,3.8,9.2,0.38,0.90,0.50,0.84,Cardiovascular,"Hoglund P and Nilsson LG (1988) Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers.  Ther. Drug Monit. 10: 401-409.  Kolle EU, Ochs HR, and Vollmer KO (1983) Pharmacokinetic model of diltiazem.  Arz. Forsch. 33: 972-977.  Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482."
Diprophylline,479-18-5,0.42,,4.8,0.8,4.0,0.88,0.95,0.96,0.97,nervous system,Zuidema J and Merkus FWHM (1981) Pharmacokinetics and pharmacodynamics of diprophylline.  Pharm. Weekbl. 3: 1320-221.
Disopyramide,671200,0.52,0.16,0.9,0.4,0.5,0.83,0.83,1.02,0.98,Cardiovascular,"Lima JJ, Haughey DB, and Leier CV (1984) Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.  J. Pharmacokinet. Biopharm. 12: 289-313. Cunningham, J. L.; Shen, D. D.; Shudo, I.; Azarnoff, Daniel L.  The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.    Clinical Pharmacokinetics  (1977),  2(5),  373-83."
Dofetilide,115256-11-6,3.3,0.36,5.2,2.1,3.1,0.90,0.96,1.03,0.91,Cardiovascular,"Gemmill JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, and Elliott HL (1991) A dose ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.  Br. J. Clin. Phaemacol. 32: 429-432.  Smith DA, Rasmussen HS, Stopher DA, and Walker DK (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.  Xenobiotica 22: 709-719."
Domperidone,57808-66-9,3.4,0.082,9.5,9.5,0.0,0.14,0.93,0.26,0.59,nervous system,"Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, and Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man.  IV.  The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.  Eur. J. Drug Metab. Pharmacokinet.  6: 61-70. "
Doxapram,309-29-5,1.2,,5.3,5.0,0.3,0.61,1.00,0.78,0.78,Respiratory and inflammation,Robson RH and Prescott LF (1979) A pharmacokinetic study of doxapram in patients and volunteers.  Br. J. Clin. Pharmacol. 7: 81-87.  
Doxifluridine,436349,0.28,0.61,11,6.7,4.3,0.40,0.90,0.63,0.71,Cancer,"Van Der Heyden, S. A. M.; Highley, M. S.; De Bruijn, E. A.; Tjaden, U. R.; Reeuwijk, H. J. E. M.; Van Slooten, H.; Van Oosterom, A. T.; Maes, R. A. A.  Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.    British Journal of Clinical Pharmacology  (1999),  47(4),  351-356. Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1988) The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.  Eur. J. Clin. Pharmacol. 34: 439-443.  Meynial D, Lopez A, Malet-Martino MC, Hoffmann JS, and Martino R (1988) Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protien binding of 5'-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine.  J. Pharm. Biomed. Anal. 6: 47-59."
Doxorubicin,23214-92-8,22,0.28,15,13.2,1.8,0.05,0.12,0.97,0.43,Cancer,"Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Piscitelli SC, Rodvold KA, Rushing DA, and Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.  Clin. Pharmacol. Ther. 53: 555-561.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.    Cancer Chemother. Pharmacol. 10: 7-10."
Doxycycline,564-25-0,0.69,0.12,0.46,0.3,0.2,0.93,1.00,0.94,0.99,Infection,"Nguyen VX, Nix DE, Gillikin S, and Schentag JJ (1989)  Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.  Antimic. Agents Chemother. 33: 434-436.  Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, and Tillement JP (1983) The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.  Br. J. Clin. Pharmacol. 16: 245-252.  Raghuram TC and Krishnaswamy K (1982) Pharmacokinetics and plasma steady-state levels of doxycycline in undernutrition.  Br. J. Clin. Pharmacol. 14: 785-789."
Drotaverine,14009-24-6,1.9,0.12,3.5,3.5,0.0,0.58,1.00,0.69,0.85,nervous system,"Bojali OO, Onyeji CO, Ogundani AO, Olugbade TA, and Ogunbona FA (1996) Pharmacokinetics and bioavailability of drotaverine in humans.  Eur. J. Drug Metab. Pharmacokinet. 21: 217-221.  Vargay Z, Deutsch T, Szatmari I, Szuts T, Varkonyi P, Kerpel-Fronius S, and Eckhardt S (1984) The fate of drtoaverine-acephyllinate in rat and man II.  Human pharmacokinetics of drotaverine-14C-acephyllinate.  Eur. J. Drug Metab. Pharmacokinet. 9: 17-29."
Enalaprilat,76420-72-9,0.38,0.62,1.6,0.0,1.6,0.25,0.25,1.00,1.00,Cardiovascular,"Hockings N, Ajayi AA, and Reid JL (1986) Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.  Br. J. Clin. Pharmacol. 21: 341-348.  Mujais  SK, Quintanilla A, Zahid M, Koch K, Shaw W, and Gibson T (1992) Renal handling of enalaprilat.    Am. J. Kidney Dis. 19: 121-125."
Encainide,66778-36-7,2.2,0.26,13,12.2,0.8,0.30,0.95,0.67,0.47,Cardiovascular,"Roden D M; Woosley R L  Clinical pharmacokinetics of encainide.    Clinical pharmacokinetics  (1988),  14(3),  141-7.   Wensing G, Monig H, Ohnhaus EE, and Hoensch HP (1991) Pharmacokinetics of encainide in patients with cirrhosis.  Cardiovasc. Drugs Ther. 5: 733-740.   C Funck-Brentano, J Turgeon, RL Woosley, and DM Roden (1989) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics.  Influence of genetic polymorphism.    Journal of Pharmacology and Experimental Therapeutics  249:  134-42.  Jaillon P (1990) Pharmacokinetics and metabolism of encainide.  Cardiovasc. Drugs Ther.  4(Suppl 3): 561-565."
Entacapone,130929-57-6,0.27,0.02,11.7,5.3,6.4,0.25,0.50,0.65,0.77,nervous system,"Heikkinen H, Saraheimo M, Antila S, Ottoila P, and Pentikainen PJ (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique.   Eur. J. Clin. Pharmacol. 56: 821-826.   Najib J (2001)  Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease. Clin. Ther. 23: 802-832."
Epristeride,119169-78-7,0.54,0.03,0.33,0.3,0.0,0.93,0.93,1.01,0.99,Others,"Benincosa LJ, Audet PR, Lundberg D, Zariffa N, and Jorkasky DK (1996) Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.  Biopharm, Drug Dispos. 17: 249-258.  Li JT, Zheng Z, and Jin J (2000) Pharmacokinetics of epristeride in healthy male volunteers.  Zhongguo Linchuang Yaolixue Zazhi 16: 424-428."
Eprosartan,133040-01-4,0.17,0.017,1.9,1.2,0.7,0.13,0.15,0.92,0.95,Cardiovascular,"Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D (1998)  Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.  Biopharm. Drug Dispos. 19: 351-356.  Kovacs SJ, Tenero DM, Martin DE, Ilson BE, and Jorkasky DK (1999) Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.  Pharmacotherapy 19: 612-619. "
Erythromycin,114-07-8,0.95,0.1,5.6,5.3,0.3,0.35,0.50,0.91,0.77,Infection,Welling PG and Craig WA (1978) Pharmacokinetics of intravenous erythromycin.  J. Pharm. Sci. 67: 1057-1059.
Estramustine phosphate,4891-15-0,0.12,,0.94,0.9,0.0,0.44,0.90,0.51,0.96,Cancer,"Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, and Hartley-Asp B (2002) Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.  J. Clin. Oncol.  20: 1115-1127.  Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, and Plym-Forshell G (1984) Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.  Eur. J. Clin. Pharmacol. 26: 113-119."
Etilefrine,709-55-7,2.1,0.77,14,10.0,4.0,0.55,1.00,0.98,0.56,Cardiovascular,"Hengstmann JH, Weyand U, and Dengler HJ (1975) The physiological disposition of etilefrine in man.  Eur. J. Clin. Pharmacol.  9: 179-187."
Etoposide,33419-42-0,0.18,0.12,0.5,0.3,0.2,0.52,0.52,1.01,0.99,Cancer,"Pfluger KH, Schmidt L, Merkel M, Jungelas H, and Havemann K (1987) Drug monitoring of etoposide (VP16-213).  Canc. Chemother. Pharmacol. 20: 59-66.  Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, et al. (1995) Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.  J. Clin. Oncol. 13: 2835-2841.  Lee, KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.   Pharm. Res. 20: 1015-1021."
Felodipine,72509-76-3,4.4,0.0036,11,11.0,0.0,0.16,0.88,0.35,0.52,Cardiovascular,"Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, and Ronn O (1985) Felodipine kinetics in healthy men.  Clin. Pharmacol. Ther. 38: 305-211."
Fenspiride,1151767,3,,2.6,0.8,1.8,0.90,1.00,0.93,0.97,Respiratory and inflammation,"Montes B, Catalan M, Roces A, Jeanniot JP, and Honorato JM (1993) Single-dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial.  Eur. J. Clin. Pharmacol. 45: 169-172.  "
Finasteride,98319-26-7,1.1,0.095,2.4,2.4,0.0,0.63,0.80,0.88,0.90,Cancer,"Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride.  Clin. Pharmacokinet. 30: 16-27.  Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, and Andersson KE (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.  Drug Metab. Dispos. 20: 148-155"
Flecainide,54143-55-4,6.1,0.52,4.9,2.8,2.1,0.70,0.81,0.99,0.88,Cardiovascular,"Wang T, Siddoway LA, Thompson KA, Conard GJ, Bergstrand RH, Kvam D, Roden DM, and Woosley RL (1988) The development and testing of intravenous dosing regimens: application to flecainide for teh suppression of ventricular arrhythmias.  Clin. Pharmacol. Ther. 43: 499-508.  Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, and DeSchepper PJ (1986) Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.  Br. J. Clin. Pharmacol. 22: 309-316.  Munafo A, Buchlin T, Tuto D, and Biollaz J (1992) The effect of low dose quinidine on the disposition of flecainide in healthy volunteers.  Eur. J. Clin. Pharmacol. 43: 441-443.  Johnston A, Muhiddin KA, and Hamer J (1982) Serum protein binding of flecainide.  Br. J. Clin. Pharmacol. 13: 606P."
Fleroxacin,79660-72-3,1.3,0.73,2.4,0.9,1.5,1.00,1.00,1.04,0.96,Infection,"Weidekamm E, Portmann R, Suter K, Partos C, Dell D, and Lucker PW (1987) Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.  Antimic. Ag. Chemother. 31: 1909-1914.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750."
Fluconazole,86386-73-4,0.75,0.89,0.31,0.1,0.2,0.90,0.95,0.95,1.00,Infection,"Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, and Gibson P (1988) Steady state parenteral kinetics of fluconazole in man.  Ann. N.Y. Acad. Sci. 544: 427-30.  Humphrey MJ, Jevons S, and Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Animic. Agents Chemother. 28: 648-653."
Flucytosine,2022-85-7,0.68,1,2,0.0,2.0,0.84,0.88,0.95,1.00,Cancer,"Cutler RE, Blair AD, and Kelly MR (1978) Flucytosine kinetics in subjects with normal and impaired renal function.  Clin. Pharmacol. Ther. 24; 333-342.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021."
Flumazenil,78755-81-4,0.8,0.58,16,16.0,0.0,0.16,0.95,0.55,0.31,nervous system," Klotz U, Ziegler G, and Reimann IW (1984)  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.  Eur. J. Clin. Pharmacol. 27: 115-117.  Janssen U, Walker S, Maier K, von Gaisberg U, and Klotz U (1989) Flumazenil disposition and elimination in cirrhosis.  Clin. Pharmacol. Ther.  46: 317-323. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, and Butterworth RF (1989) Pharmacokinetics of benzodiazepine antagonist RO 15-1788 in cirrhotic patients with moderate or severe liver dysfunction.  Hepatology  10: 969-972. "
Flupirtine,56995-20-1,1.1,0.15,1.6,1.3,0.3,0.90,1.00,0.96,0.94,nervous system,Hlavica VP and Niebch G (1985) Untersuchungen zur pharmakokinetik und biotransformation des analgetikums flupirtin beim menschen.  Arz. Forsch. 35: 67-74. 
Fluvastatin,93957-54-1,0.42,0.0079,16,16.0,0.0,0.24,1.00,0.79,0.30,Cardiovascular,"Tse F L; Jaffe J M; Troendle A  Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.    Journal of clinical pharmacology  (1992),  32(7),  630-8.  Tse FLS, Nickerson DF, and Yardley WS (1993) Binding of fluvastatin to blood cells and plasma proteins.  J. Pharm. Sci. 82: 942-947."
Folinic acid,1492-18-8,0.25,0.087,5.3,4.5,0.8,0.04,0.36,0.14,0.80,Cancer,"Greiner PO, Zittoun J, Marquet J, and Cheron JM (1989) Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br. J. Clin. Pharmacol. 28: 289-295.  Christophidis N, Louis WJ, Lucas I, Moon W, and Vajda FJ (1981) Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.  Cancer Chemother Pharmacol. 6: 59-64.  "
Foscarnet,63585-09-1,0.5,0.85,2.1,0.4,1.7,0.13,0.17,0.78,0.98,Infection,"Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.    Clin. Pharmacol. Ther. 57: 403-412.  Sjovall J, Bergdahl S, Movin G, Ogenstad S, and Saarimaki M (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.  Antimic. Agents Chemother. 33: 1023-1031."
Fosfomycin,23155-02-4,0.32,1,2,0.0,2.0,0.31,0.31,1.00,1.00,Infection,"Goto M, Sugiyama M, Nakajima S, and Yamashina H (1981) Fosfomycin kinetics after intravenous and oral administration to human volunteers.    Antimic. Agents Chemother. 20: 393-397.  Potel G, Meignier M, Baron D, Reynaud A, Touze MD, and Cortieu AL (1989) Pharmacokinetics of fosfomycin in normal and burn patients.  Effect of probenecid.  Drugs Exptl. Clin. Res. 15: 177-184.  Kestle DG and Kirby WMM (1970) Clinical pharmacology and in vitro activity of phosphonomycin.  Antimic. Agents Chemother. 332-337 (Chem Abstr. 75:62036)."
Frovatriptan,158747-02-5,3.6,0.85,2.5,1.5,1.0,0.26,0.40,0.69,0.94,nervous system,"Buchan P, Keywood C, Wade A, and Ward C (2002) Clinical pharmacokinetics of frovatriptan.  Headache  42(Suppl 2): s54-s62."
Furosemide,54-31-9,0.12,0.012,2.4,0.7,1.7,0.51,0.61,0.86,0.97,Cardiovascular,"Hammerlund MM, Paalzow LK, and Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration.  Application of moment analysis. Eur. J. Clin. Pharmacol. 26: 197-207. Smith DE, Lin ET, and Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.  Drug Metab. Dispos. 8: 337-342.  "
Gabapentin,60142-96-3,0.71,0.97,1.7,0.0,1.7,0.60,0.60,1.00,1.00,nervous system,"Vollmer KO, Anhut H, Thomann P, Wagner F, and Jahnchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin.  Adv. Epileptol. 17: 209-211.  Neurontin Product Label."
Ganciclovir,82410-32-0,1,0.99,4.6,0.5,4.1,0.09,0.09,1.02,0.98,Infection,"Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, and Smith RB (1995) Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus seropositive patients.  Clin. Ther.  17: 425-432.   Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.  Clin. Pharmacol. Ther. 57: 403-412.  Cytovene-IV Product Label"
Gatifloxacin,160738-57-8,1.7,0.8,2.8,0.5,2.3,0.96,0.96,1.02,0.98,Infection,"Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, and Grasela DM (2000) A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.  Pharmacotherapy  20: 49S-58S.  Perry C, Balfour J, and Lamb H (1999) Gatifloxacin.  Drugs 58: 683-698."
Genaconazole,120924-80-3,0.62,,0.19,0.0,0.2,1.00,1.00,1.00,1.00,Infection,"Mojavrian P, Radwanski E, Affirme MB, Cayen MN, and Lin CC (1994) Pharmacokinetics of the triazole antifungal agent geneconazole in healthy men after oral and intravenous administration.  Antimic. Agents Chemother.  38: 2758-2762."
Gentamicin,1405-41-0,0.33,1,1,0.3,0.7,0.00,0.00,1.00,0.99,Infection,"Creasey, William A.; Adamovics, John; Dhruv, Rohini; Platt, Thomas B.; Sugerman, A. Arthur.  Pharmacokinetic interaction of aztreonam with other antibiotics.    Journal of Clinical Pharmacology  (1984),  24(4),  174-80. Bertino JS, Booker LA, Franck P, and Rybicki B (1991) Gentamicin pharmacokinetics in patients with malignancies.  Antimic. Agents Chemother.  35: 1501-1503.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216."
Ginkgolide A,15291-75-5,0.62,,2.3,0.7,1.7,0.80,0.90,0.91,0.97,Respiratory and inflammation,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144."
Ginkgolide B,15291-77-7,0.91,,2.3,1.3,1.0,0.88,0.90,1.03,0.95,Respiratory and inflammation,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144."
Glimepiride,93479-97-1,0.19,0.005,0.5,0.5,0.0,1.00,1.00,1.02,0.98,Gastrointestinal/Metabolism,"Badian M, Korn A, Lehr KH, Malerczyk V, and Waldhaust W (1994) Absolute bioavailability of glimepiride (Amaryl) after oral administration.  Drug Metab. Drug Inter. 11: 331-339.  Amaryl Product Label."
Glipizide,29094-61-9,0.16,0.02,0.56,0.5,0.0,0.95,1.00,0.97,0.98,Gastrointestinal/Metabolism,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1983) Pharmacokinetics and pharmacodynamics of glipizide in health volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 21: 98-107.  Fuccella LM, Tamassia V, and Valzelli G (1973) Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.  J. Clin. Pharmacol. New Drugs 13: 68-75."
Glyburide,10238-21-8,0.08,0.021,0.82,0.8,0.0,0.95,1.00,0.99,0.96,Gastrointestinal/Metabolism,"Jonsson A, Chan JCN, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JAJH, and Melander A (2000) Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes.    Eur. J. Clin. Pharmacol. 55: 721-727. Spraul M, Streeck A, Nieradzik M, and Berger M (1989) Uniform elimination pattern for glibenclamide in healthy caucasian males.  Arz. Forsch. 39: 1449-1450. George S, McBurney A, and Cole A (1990) Possible protein binding displacement interaction between glibenclamide and metolazone.  Eur. J. Clin. Pharmacol. 38: 93-95."
Granisetron,109889-09-0,3.7,0.35,9.1,8.1,1.0,0.64,1.00,0.99,0.65,nervous system,"Allen A, Asgill CC, Pierce DM, Upward J, and Zussman BD (1994) Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.  Eur. J. Clin. Pharmacol.  46: 159-162.  Kytril Product Label."
Guanfacine,29110-47-2,5.6,0.28,5.9,2.9,3.0,0.81,1.00,0.93,0.87,Cardiovascular,"Carchman SH, Crowe JT, and Wright GJ (1987) The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.  J. Clin. Pharmacol. 27: 762-767."
Haloperidol,52-86-8,17,0.08,7.8,7.7,0.1,0.60,1.00,0.90,0.66,nervous system,"Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, and Hollister LE (1983) Haloperidol kinetics after oral and intravenous administration.  Clin. Pharmacol. Ther. 33: 477-484.  Chang WH, Lam YWF, Jann MW, and Chen H (1992) Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.  Psychopharmacology 106: 517-522.  Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, Lindberg A, and Lindstrom L (1987) Pharmacokinetics of haloperidol in psychotic patients.  Psychopharmacology 91: 410-414.  Forsman A and Ohman R (1977) Studies on serum protein binding of haloperidol.  Curr. Ther. Res. 21: 245-255. Forsman A et al. 1977 Curr Ther res 21 606-617"
Hydroflumethazide,135-09-1,2.2,,9.7,0.7,9.0,0.62,0.62,1.03,0.97,Cardiovascular,Broers O and Jacobsen S (1979) Distribution and elimination of hydroflumethiazide in man.  Eur. J. Clin. Pharmacol. 16: 125-131.
Hydroxyurea,127-07-1,0.52,1,1.5,1.0,0.5,1.00,1.00,1.04,0.96,Cancer,"Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.  Blood 91:1533-1541"
Ibuprofen,15687-27-1,0.15,0.006,0.82,0.8,0.0,0.95,0.95,1.04,0.96,Respiratory and inflammation,"Martin W, Koselowske G, Toberich H, Kerkmann T, Mangold B, and Augustin J (1990) Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man.  Biopharm. Drug Dispos. 11: 265-278.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021."
Idazoxan,79944-56-2,3.3,,10,10.0,0.0,0.34,0.95,0.63,0.57,nervous system,"Muir NC, Lloyd-Jones JG, Nichols JD, and Clifford JM (1986) The pharmacokinetics after intravenous and oral administration in man of the alpha2-adrenoreceptor antagonist idazoxan (RX781094).  Eur. J. Clin. Pharmacol.  29: 743-745."
Ifosfamide,3778-73-2,0.62,1,1.1,0.5,0.6,0.92,1.00,0.94,0.98,Cancer,"Corlett SA, Parker D, and Chrystyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.  Br. J. Clin. Pharmacol. 39: 452-455.  "
Imipenem,64221-86-9,0.24,0.86,3,1.5,1.5,0.50,1.00,0.53,0.93,Infection,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3): 227-235.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.
Indomethacin,53-86-1,0.096,0.01,1.3,1.1,0.2,1.00,1.00,1.05,0.95,Respiratory and inflammation,"Yeh KC, Berger ET, Breault GO, and Lei BE (1982) Effect of sustained release on the pharmacokinetic profile of indomethacin in man.  Biopharm. Drug Dispos. 3: 219-230.  Indocin Product Label."
Isosorbide-5-Mononitrate,16051-77-7,0.7,1,2,1.9,0.1,0.93,1.00,1.01,0.92,Cardiovascular,"Major RM, Taylor T, Chasseaud LF, Darragh A, and Lambe RF (1984) Isosorbide 5-mononitrate kinetics.  Clin. Pharmacol. Ther. 35: 653-659.  Straehl P, Galeazzi RL, and Soliva M (1984) Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.  Clin. Pharmacol. Ther.  36: 485-491."
Isoxicam,34552-84-6,0.19,0.035,0.07,0.1,0.0,0.97,1.00,0.97,1.00,Respiratory and inflammation,"Kolle EU and Vollmer KO (1986) Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.  Br. J. Clin. Pharmacol. 22(Suppl 2): 135S-141S.  Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, and Tillement JP (1997) Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.  Pharm. Res. 14: 650-656."
Itraconazole,84625-61-6,7.4,0.002,5.1,5.1,0.0,0.55,0.85,0.83,0.78,Infection,"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview.  Mycoses  32(Suppl 1): 67-87.  "
Ketanserin,74050-98-9,3.9,0.055,6.7,6.6,0.1,0.50,1.00,0.70,0.71,Cardiovascular,"Heykants J, Van Peer A, Woestenborghs R, Gould S, and Mills J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 31: 343-350.  Persson B, Pettersson A, and Hedner T (1987) Pharmacokinetics of ketanserin in patients wuith essential hypertension.  Eur. J. Clin. Pharmacol. 32: 259-265.  Trenk D, Mosler A, Kirch W, Meinertz T, and Jahnchen E (1983) Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.  J. Cardiovasc. Pharmacol. 5: 1034-1039.  Barendregt JN, Van Peer A, Van Der Hoeven JG, Van Oene JC, and Tjandra YI (1990) Ketanserin pharmacokinetics in patients with renal failure. Br. J. Clin. Pharmacol. 29: 715-723.  Reimann IW, Okonkwo PO, and Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur. J. Clin. Pharmacol. 25: 73-76.  "
Ketoprofen,22071-15-4,0.13,0.008,1.6,1.1,0.5,0.85,0.92,0.97,0.95,Respiratory and inflammation,"Delbarre F; Roucayrol J C; Amor B; Ingrand J; Bourat G; Fournel J; Courjaret J  Pharmacokinetic study of ketoprofen (19.583 R.P.) in man using the tritiated compound.    Scandinavian journal of rheumatology. Supplement  (1976),  1976(0),  45-52. Debruyne D, de Ligny BH, Ryckelynck JP, Albessard F, and Moulin M (1987) Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion.  Clin. Pharmacokinet. 12: 214-221.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021."
Ketorolac,74103-06-3,0.11,0.0068,0.35,0.2,0.2,1.00,1.00,1.01,0.99,Respiratory and inflammation,"Jung D, Mroszczak E, and Bynum L (1988) Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 35: 423-425.  Reed MD, Myers CM, and Blumer JL (2001) Influence of midazolam on the protein binding of ketorolac.  Curr. Ther. Res.  62: 558-565.  Mroszczak EJ, Lee FM, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, and Cho DK (1987) Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.  Drug Metab. Dispos. 15: 618-626"
Lamivudine,134678-17-4,1.3,0.94,4.8,1.4,3.4,0.87,1.00,0.93,0.94,Infection,"Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, and Hussey EK (1995) Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35: 1174-1180.  Takubo T, Hirayama S, Moriya T, Minamide Y, Kato T, Nakamura R, and Kinami J (1997) Studies on the metabolic fate of lamivudine (II): tissue distribution, transfer into fetus and milk, plasma protein binding and distribution to erythrocytes of lamivudine in rats.  Yakubutsu Dotai 12: 92-101."
Lamotrigine,84057-84-1,,,0.6,0.6,0.0,0.98,1.00,1.00,0.98,nervous system,"Yuen WC, Peck AW (1988) Lamotrigine pharmacokinetics: oral and iv infusion in man. Br J Clin pharmacol 26 242P"
Lansoprazole,103577-45-3,0.28,0.021,4.4,4.4,0.0,0.85,1.00,1.05,0.81,Gastrointestinal/Metabolism,"Gerloff J, Mignot A, Barth H, and Heintze K (1996) Pharmacokinetics and absolute bioavailability of lansoprazole.  Eur. J. Clin. Pharmacol. 50: 293-297.  Freston JW, Pilmer BL, Chiu YL, Wang Q, Stolle JC, Griffin JS, and Lee CQ (2004) Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.  Alimentary Pharmacol. Ther. 19: 1111-1122.  Karol MD, Machinist JM, and Cavanaugh JM (1995) Pharmacokinetics of lansoprazole in hemodialysis patients.  J. Clin. Pharmacol.  35: 815-820."
Letrozole,112809-51-5,1.9,0.41,0.57,0.6,0.0,1.00,1.00,1.02,0.98,Cancer,"Sioufi A, Gauducheau N, Pineau V, Marfil F, Jaouen A, Cardot JM, Godbillon J, Czendlik C, Howald H, Pfister C, and Vreeland F (1997) Absolute bioavailability of letrozole in healthy postmenopausal women.  Biopharm Drug Dispos. 18: 779-89.   Colussi DM, Parisot CY, and Lefevre GY (1998) Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.  J. Clin. Pharmacol. 38: 727"
Levofloxacin,100986-85-4,1.2,0.75,1.9,0.5,1.4,0.99,1.00,1.01,0.98,Infection,"Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, and Pea F (2003) Pharmacokinetic aspects of levofloxacin 500mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.  J. Antimic. Chemother. 51: 101-106.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41: 741-750."
Levomepromazine,60-99-1,12,,9.9,5.9,4.0,0.21,0.53,0.53,0.74,nervous system,"Bagli M, Hoflich G, Rao, ML, Langer M, Baumann P, Kolbinger M, Barlage U, Kasper S, and Moller HJ (1995) Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.  Int. J. Clin. Pharmacol. Ther. 33: 646-652. Clin Pharmacol Ther. 1976 Apr;19(4):435-42."
Levoprotiline,76496-68-9,,,12.3,12.1,0.2,0.40,1.00,0.84,0.47,nervous system,"Kaiser G; Ackermann R; Dieterle W; Reimann I W; Bieck P R  Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers.    Biopharmaceutics & drug disposition  (1992),  13(2),  83-93.  "
Linezolid,165800-03-3,0.58,0.69,1.8,1.2,0.6,1.00,1.00,1.05,0.95,Infection,"Stalker DJ, Jungbluth GL, Hopkins NK, and Batts DH (2003) Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.  J. Antimic. Chemother. 51: 1239-1246.  Zyvox Product Label."
Lisinopril,76547-98-3,0.89,1,1.2,0.0,1.2,0.25,0.28,0.89,1.00,Cardiovascular,"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, and Junggren IL (1989) Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers.  Biopharm. Drug Dispos. 10: 397-409.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482. "
Lorazepam,846-49-1,1.3,0.09,1,1.0,0.0,0.93,1.00,0.97,0.96,nervous system,"Wermeling DPH, Miller JL, Archer SM, Manaligod JM, and Rudy AC (2001) Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 41: 1225-1231.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson, GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.  "
Lorcainide,59729-31-6,6.6,0.15,16,15.7,0.3,0.03,0.70,0.13,0.32,Cardiovascular,"Klotz U, Mueller-Seydlitz P, and Heimburg P (1979) Disposition and antiarrythmic effect of lorcainide.  Int. J. Clin. Pharmacol. Biopharm. 17: 152-158.  Klotz U, Mueller-Seydlitz P, and Heimburg P (1978) Pharmacokinetics of lorcainide in man:  a new antiarrhythmic agent.  Clin. Pharmacokinet. 3: 407-418."
Lormetazepam,848-75-9,1.6,0.12,4,4.0,0.0,0.80,1.00,0.97,0.83,nervous system,"Humpel M, Illi V, Milius W, Wendt H, and Kurowski M (1979) The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 4: 237-243."
Losartan,114798-26-4,0.37,0.01,8.2,7.3,0.9,0.36,0.80,0.66,0.68,Cardiovascular," Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.   Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58: 641-649.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  "
Lovastatin,075330-75-5,0.87,0.043,7.2,6.5,0.7,0.05,0.31,0.22,0.72,Cardiovascular,"Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S (1989) The physiological disposition of lovastatin.  Drug Metab Dispos. 17: 166-173."
Loxiglumide,107097-80-3,0.24,,1,1.0,0.0,0.97,1.00,1.01,0.96,Gastrointestinal/Metabolism,"Setnikar I, Chiste R, Makovec F, Rovati LC, and Warrington SJ (1988) Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.  Arz. Forsch. 38: 716-720."
Mebendazole,31431-39-7,1.2,0.086,15,14.8,0.2,0.22,1.00,0.62,0.36,Infection,"Dawson M, Braithwaite PA, Roberts MS, Watson TR (1985) The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.  Br. J. Clin. Pharmacol. 19: 79-86."
Melagatran,159776-70-2,0.23,0.93,1.9,0.3,1.6,0.06,0.15,0.39,0.99,Cardiovascular,"Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab. Dispos. 31: 294-305."
Meloxicam,71125-38-7,0.15,0.003,0.12,0.1,0.0,0.90,0.90,1.01,0.99,Respiratory and inflammation,"Narjes H, Turck D, Busch U, Heinzel G, and Nehmiz G (1996) Pharmacokinetics and tolerability of meloxicam after i.m. administration.  Br. J. Clin. Pharmacol. 41: 135-139.  Busch U, Heinzel G, and Narjes H (1995) The effect of cholestyramine on the pharmaciokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.  Eur. J. Clin. Pharmacol. 48: 269-272.   Turck D, Busch U, Heinzel G, and Narjes H (1997) Clinical pharmacokinetics of meloxicam.  Arz. Forsch. 47: 253-258. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, and Kummer M (1995) Meloxicam. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dispos. 23: 1206-1213.  Tuerck D, Schwarz A, Hoeffler D, Narjes HH, Nehmiz G, and Heinzel G (1996) Pharmacokinetics of meloxicam in patients with end-stage renal failure on hemodialysis. A comparison with healthy volunteers.  Eur. J. Clin. Pharmacol.  51: 309-313."
Metformin,657-24-9,0.64,1,7.4,0.0,7.4,0.52,0.52,1.00,1.00,Gastrointestinal/Metabolism,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man.  Eur. J. Clin. Pharmacol. 16: 195-202."
Methadone,76-99-3,4.4,0.21,1.7,1.3,0.4,0.92,1.00,0.97,0.94,nervous system,"Nilsson MI, Gronbladh L, Widerlov E, and Anggard E (1983) Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.  Eur. J. Clin. Pharmacol. 25: 497-501.  Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, and Sjoegren P (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients.  Ther. Drug Monit. 18: 221-227.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230. "
Methotrexate,59-05-2,0.43,0.37,2.1,0.4,1.7,0.70,0.70,1.02,0.98,Cancer,"Bore P, Bruno R, Lena N, Favre R, and Cano JP (1987) Methotrexate and 7-hydroxymethotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate.  Eur. J. Canc. Clin. Oncol. 23: 1385-1390.  Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, and Furst DE (1989) Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.  J. Pharm. Sci. 78: 165-171.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180."
Methyldopa,555-30-6,0.69,0.85,3.5,1.4,2.1,0.32,0.40,0.85,0.94,Cardiovascular,"Skerjanec A, Campbell NRC, Robertson S, and Tam YK (1995) Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects.  J. Clin. Pharmacol. 35: 275-280.  Stenbaek O, Myhre E, Rugstag HE, Arnold E, and Hansen T (1977) Pharmacokinetics of methyldopa in healthy man.  Eur. J. Clin. Pharmacol. 12: 117-123.  Myhre E, Rugstad HE, and Hansen T (1982) Clinical pharmacokinetics of methyldopa.  Clin. Pharmacokinet. 7: 221-233."
Metoclopramide,364-62-5,3.2,0.6,5.7,4.6,1.1,0.76,1.00,0.95,0.80,nervous system,"Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, and Taburet AM (1991) Pharmacokinetics of metoclopramide in patients with liver cirrhosis.  Br. J. Clin. Pharmacol. 31: 185-187.  Webb D, Buss DC, Fifield R, Bateman DN, and Routledge PA  The plasma protein binding of metoclopramide in health and renal disease. Br. J. Clin. Pharmacol. 21: 334-336."
Metolazone,17560-51-9,1.6,0.05,1.4,0.3,1.1,0.26,0.64,0.41,0.99,Cardiovascular,"Tilstone WJ, Dargie H, Dargie EN, Morgan HC, and Kennedy AC (1974) Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.  Clin. Pharmacol. Ther. 16: 322-329."
Metoprolol,37350-58-6,3.1,0.88,13,12.4,0.7,0.38,0.98,0.84,0.46,Cardiovascular,"Jordo L, Attman PO, Aurell M, Johansson L, Johnsson G, and Regardh CG (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.  Clin. Pharmacokinet. 5: 169-180.  Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, and Perrier DG (1987) Influence of smoking and gender on the disposition kinetics of metoprolol.  Eur. J. Clin. Pharmacol. 33: 355-361.  Richard J, Cardot JM, and Godbillon J (1994) Inter-and intra-subject variability of metoprolol kinetics after intravenous administration.  Eur. J. Drug metab. Pharmacokinet. 19: 157-162.  Johnsson G and Regardh CG (1976) Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.  Clin. Pharmacokinet. 1: 233-263."
Metronidazole,000443-48-1,0.4,0.96,0.85,0.7,0.2,0.99,1.00,1.02,0.97,Infection,"Sanvordekar DR, Chien YW, Lin TK, Lambert HJ (1975) Binding of metronidaole and its derivatives to plasma proteins: an assessment of drug binding phenomenon.  J. Pharm Sci. 64: 1797-1803.   Bergan T and Thorsteinsson SB (1986) Pharmacokinetics of metronidazole and its metabolites in reduced renal function.  Chemotherapy 32: 305-318."
Midazolam,59467-70-8,1.1,0.017,5.3,5.3,0.0,0.38,0.90,0.55,0.77,nervous system,"Heizmann P, Eckert M, and Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man.  Br. J. Clin. Pharmacol. 16: 43s-49s.  Pentikainen PJ, Valisalmi L, Himberg JJ, and Crevoisier C (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.  J. Clin. Pharmacol. 29: 272-277.  "
Miglitol,72432-03-2,0.28,1,1.7,0.0,1.7,0.59,0.59,1.00,1.00,Gastrointestinal/Metabolism,"Ahr AH, Boberg M, Brendel E, Krouse HP, and Steinke W (1997) Pharmacokinetics of miglitol.  Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.  Arz. Forsch. 47: 734-745."
Milrinone,78415-72-2,0.25,0.035,6.2,1.2,5.0,0.92,1.00,0.97,0.95,Cardiovascular,"Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, and Edelson J (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers.  J. Pharm. Sci. 73: 1438-1441.  Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, and Greenslade D (1995) Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.  J. Pharm. Pharmacol. 47: 651-655. Kirsten, Roland; Nelson, Karen; Kirsten, Daniel; Heintz, Bernhard.  Clinical pharmacokinetics of vasodilators. Part II.    Clinical Pharmacokinetics  (1998),  35(1),  9-36."
Minocycline,10118-90-8,1.6,,1.2,1.1,0.1,1.00,1.00,1.05,0.95,Infection,"Simon VC, Malerczyk V, Preuss I, Schmidt K, and Grahman H (1976) In vitro aktivitat und pharmakokinetik von minocyclin.  Arz. Forsch. 26: 556-560."
Mirtazapine,61337-67-5,4.2,0.15,8,7.7,0.3,0.50,0.80,0.94,0.67,nervous system,"Voortman G and Paanakker JE (1995) Bioavailability of mirtazepine from Remeron tablets after single and multiple oral dosing.  Human Psychopharmacol. 10: s83-s96.  Timmer CJ, Sitsen JM, and Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine.  Clin. Pharmacokinet. 38: 461-74."
Moclobemide,71320-77-9,1.1,0.77,10,10.0,0.1,0.44,0.98,0.79,0.57,nervous system,"Raaflaub J, Haefelfinger P, and Trautman KH (1984) Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.  Arz. Forsch. 34: 80-82.   Schoerlin MP, Mayersohn M, Korn A, and Eggers H (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.  Clin. Pharmacl. Ther. 42: 395-404.  Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, and Pfefen JP (1991) Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.  Clin. Pharmacol. Ther. 49: 32-38.  Schoerlin MP, Horber FF, Frey FJ, and Mayersohn M (1990) Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.  J. Clin. Pharmacol. 30: 272-284.  Schoerlin MP and Guentert TW (1989) Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human.  Psychiatrische Praxis  16(Suppl 1): 11-17."
Montelukast,158966-92-8,0.15,0.002,0.68,0.7,0.0,0.62,0.80,0.80,0.97,Respiratory and inflammation,"Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, and Cheng H (1997) Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.  Biopharm. Drug Dispos. 18: 769-777.  Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, and Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.  Pharm. Res. 13: 445-448."
Moxifloxacin,354812-41-2,1.4,0.6,2.4,1.9,0.5,0.86,0.90,1.04,0.92,Infection,Avelox IV Product Label
Moxonidine,75438-57-2,1.8,0.93,11,3.5,7.5,0.88,0.99,1.05,0.85,Cardiovascular,"Wise, Stephen D.; Chan, Clark; Schaefer, Hans G.; He, Minxia M.; Pouliquen, Isabelle J.; Mitchell, Malcolm I.  Quinidine does not affect the renal clearance of moxonidine.    British Journal of Clinical Pharmacology  (2002),  54(3),  251-254.  Theodor R, Weimann HJ, Weber W, and Michaelis K (1991) Absolute bioavailability of moxonidine.  Eur. J. Drug Met. and Pharmacokin. 16: 153-159.  Schaefer HG, Toublanc N, and Weimann HJ (1998) The pharmacokinetics of moxonidine.  Rev. Contemp. Pharmacother.  9: 481-490."
Nadolol,42200-33-9,1.9,0.14,2.9,1.1,1.8,0.34,0.57,0.63,0.95,Cardiovascular,"Morrison RA, Singhvi SM, Creasey WA, and Willard DA (1988) Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.  Eur. J. Clin. Pharmacol. 33: 625-628.  Patel L, Johnston A, and Turner P (1984) Nadolol binding to human serum proteins.  J. Pharm. Pharmacol. 36: 414-415."
Naratriptan,121679-13-8,2.4,0.7,6.6,3.5,3.1,0.68,0.80,1.00,0.85,nervous system,Amerge Product Label.
Nateglinide,105816-04-4,0.15,0.029,1.8,1.7,0.1,0.72,0.90,0.86,0.93,Gastrointestinal/Metabolism,"Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, Mcleod JF, and Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans.  Drug Metab. Dispos. 29: 415-421.  Choudhury S, Hirschberg Y, Filipek R, Lasseter K, and McLeod JF (2000) Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.  J. Clin. Pharmacol. 40: 634-640."
Nefazodone,83366-66-9,0.51,0.01,7.5,7.1,0.4,0.19,1.00,0.28,0.69,nervous system,"Barbhaiya RH, Dandekar KA, and Greene DS (1996) Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.  Drug Metab. Dispos. 24:  91-5.  PPB data from http://www.drugs.com/ppa/nefazodone_hydrochloride.html"
Neostigmine,59-99-4,0.74,,9.2,3.8,5.4,0.02,0.05,0.36,0.84,nervous system,"Aquilonius S M; Hartvig P  Clinical pharmacokinetics of cholinesterase inhibitors.    Clinical pharmacokinetics  (1986),  11(3),  236-49. Morris RB, Cronnelly R, Miller RD, Stanski DR, and Fahey MR (1981) Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.  Anesthesiol. 54: 399-402."
Nevirapine,129618-40-2,1.3,0.32,0.3,0.3,0.0,0.93,1.00,0.94,0.99,Infection,"Riska, Paul; Lamson, Michael; Macgregor, Thomas; Sabo, John; Hattox, Susan; Pav, Joseph; Keirns, James.  Disposition and biotransformation of the antiretroviral drug nevirapine in humans.    Drug Metabolism and Disposition  (1999),  27(8),  895-901.  Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, and  Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.  Biopharm. Drug Dispos. 20: 285-291.  Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R,  Reynolds HE, Garazzino S, Sinicco A,  Khoo SH, Back DJ, and Di Perri G (2004) The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests.  AIDS Res. Human Retroviruses  20: 716-722."
Nicardipine,55985-32-5,1,0.01,11,10.9,0.1,0.11,0.95,0.21,0.53,Cardiovascular,"Guerret M, Cheymol G, Hubert M, Julien-Larose C, and Lavene D (1989) Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.  Eur. J.Clin. Pharmacol. 37: 381-385.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  "
Nicotine,54-11-5,2.6,0.95,18,15.0,3.0,0.30,1.00,0.86,0.35,nervous system,"Busto U; Bendayan R; Sellers E M  Clinical pharmacokinetics of non-opiate abused drugs.    Clinical pharmacokinetics  (1989),  16(1),  1-26. Benowitz NL, Jacob P, Jones RT, and Rosenberg J (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.  J. Pharmacol. Exp. Ther. 221: 368-372. "
Nifedipine,21829-25-4,0.79,0.044,7.3,7.3,0.0,0.50,1.00,0.73,0.68,Cardiovascular,"Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, and George CF (1995) Factors affecting the absolute bioavailability of nifedipine.  Br. J. Clin. Pharmacol. 40: 51-58.  Robertson DRC, Waller DG, Renwick AG, and George CF (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.  Br. J. Clin. Pharmacol. 25: 297-305.  Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, and Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin. Pharmacol. Ther. 40: 21-28.  Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, and Breimer DD (1984) Nifedipine: kinetics and dynamics in healthy subjects.  Clin. Pharmacol. Ther. 35: 742-749.    Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  "
Nimodipine,66085-59-4,1.1,0.016,15,15.0,0.0,0.12,0.90,0.38,0.35,Cardiovascular,"Muck W, Breuel HP, and Kuhlmann J (1996) The influence of age on the pharmacokinetics of nimodipine.  Int. J. Clin. Pharmacol. Ther. 34: 293-298.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.    Hynymen M, Siltanen T, Sahlman A, Pohjasvaara T, Muck W, and Kaste M (1995) Continuous infusion of nimodipine during coronary artery surgery: hemodynamics and pharmacokinetic study.  Br. J. Anaesth.  74: 526-533."
Nisoldipine,63675-72-9,5.5,0.003,15,15.0,0.0,0.04,0.90,0.13,0.35,Cardiovascular,"van Harten J, van Brummelen P, Lodewijks MTM, Danhof M, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.  Clin. Pharmacol. Ther. 43: 332-341.  van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, and Breimer DD (1988) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 387-394.  "
Nitrazepam,146-22-5,1.7,0.13,0.86,0.9,0.0,0.78,0.78,1.04,0.96,nervous system,"Jochemsen R, VanBeusekom BR, Spoelstra P, Janssens AR, and Breimer DD (1983) Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.  Br. J. Clin. Pharmacol. 15: 295-302.  Jochemsen R, Hogendoorn JJH, Dingemanse J, Hermans J, Boeijinga JK, and Breimer DD (1982) Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.  J. Pharmacokinet. Biopharm. 10: 231-245."
Nizatidine,76963-41-2,1,0.65,9.8,2.5,7.4,0.94,1.00,1.05,0.89,Gastrointestinal/Metabolism,"Callaghan, J. T.; Bergstrom, R. F.; Rubin, A.; Chernish, S.; Crabtree, R.; Knadler, M. P.; Obermeyer, B.; Offen, W. W.; Schneck, D. W.; et al.  A pharmacokinetic profile of nizatidine in man.    Fortschritte der Medizin  (1989),  107(Sonderh. 1),  9-16.  Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, and Callaghan JT, (1988) Nizatidine disposition in subjects with normal and imparired renal function.  Clin. Pharmacol. Ther. 43: 688-695.  Knadler MP, Bergestrom RF, Callaghan JT, and Rubin A (1986) Nizatidine, an H2-blocker.  Its metabolism and disposition in man.  Drug Metab. Dispos. 14: 175-82"
Nomifensine,24526-64-5,6,0.4,22,9.5,12.5,0.27,1.00,0.46,0.59,nervous system,"Lindberg RLP, Syvalahti EKG, and Pihlajamaki KK (1986) Disposition of nomifensine after acute and prolonged dosing.  Clin. Pharmacol. Ther. 39: 384-388.  Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species.  Arz. Forsch. 28: 58-64"
Nortriptyline,894-71-3,22,0.12,10,9.8,0.2,0.51,1.00,0.89,0.57,nervous system,"Overo KF, Gram LF, and Hansen V (1977) Interaction of perphenazine with the kinetics of nortriptyline.  Acta Pharmacol. Toxicol. 40: 97-105.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265."
Ofloxacin,82419-36-1,1.6,0.75,3.5,0.8,2.7,1.00,1.00,1.04,0.97,Infection,"Gascon AR, Campo, E, Hernandez RM, Calvo B, Errasti J, and Pedraz JL (1998) Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.  Clin. Drug Invest. 15: 491-496.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750."
Olsalazine,15722-48-2,0.07,,1.2,0.9,0.3,0.02,0.20,0.10,0.96,Gastrointestinal/Metabolism,Ryde EM and Ahnfelt NO (1988) The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.  Eur. J. Clin. Pharmacol. 34: 481-488.
Omeprazole,73590-58-6,0.24,0.05,8.4,8.3,0.1,0.53,0.95,0.87,0.64,Gastrointestinal/Metabolism,"Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, and Skanberg I (1990) The pharmacokinetics of omeprazole in humans-a study of single intravenous and oral doses.  Ther. Drug Monit. 12: 163-172.  Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, and Skanberg I (1985) Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.  Scand. J Gastroent.108(Suppl): 79-94."
Ondansetron,99614-02-5,1.8,0.27,5.8,5.5,0.3,0.62,1.00,0.82,0.76,Gastrointestinal/Metabolism,"Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, and Powell JR (1992) Age and gender effects on ondansetron pharmacokinetics:  evaluation of healthy aged volunteers.  Clin. Pharmacol. Ther. 51: 51-55..  Zofran Product Label."
Oseltamivir acid,187227-45-8,0.37,0.97,4.8,0.3,4.5,0.79,0.80,1.00,0.99,Infection,"He G, Massarella J, and Ward P (1999) Clinical pharmacokinetics of the progrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37: 471-484."
Oxazepam,604-75-1,0.59,0.04,1.1,0.2,0.9,0.93,0.93,1.01,0.99,nervous system,"Sonne J, Loft S, Dossing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, and Andreasen PB (1988) Bioavailability and pharmacokinetics of oxazepam.  Eur. J. Clin. Pharmacol. 35: 385-389.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.  Desmond PV, Roberts RK,, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175."
Oxiracetam,62613-82-5,0.55,,1.8,0.1,1.7,0.75,0.75,1.00,1.00,nervous system,"Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, and Crema A (1984) Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet.  3: 267-274."
Pantoprazole,102625-70-7,6.3,0.38,2.2,2.2,0.0,0.77,1.00,0.85,0.90,Gastrointestinal/Metabolism,"Pue MA, Laroche J, Meineke I, and deMey C (1993) Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.  Eur. J. Clin. Pharmacol. 44: 575-578.  Huber R; Hartmann M; Bliesath H; Luhmann R; Steinijans V W; Zech K  Pharmacokinetics of pantoprazole in man.    International journal of clinical pharmacology and therapeutics  (1996),  34(1 Suppl),  S7-16"
Papaverine,58-74-2,0.95,0.073,11,11.0,0.0,0.28,1.00,0.54,0.52,Cardiovascular,"Belpaire F M; Rosseel M T; Bogaert M G  Metabolism of papaverine IV. Urinary elimination of papaverine metabolites in man.    Xenobiotica; the fate of foreign compounds in biological systems  (1978),  8(5),  297-300. Garrett ER, Roseboom H, Green JR, and Schuermann W (1978) Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms.  Int. J. Clin. Pharmacol. Biopharm.  16: 193-208.  Berg G, Jonsson KA, Hammar M, and Norlander B (1988) Variable bioavailability of papaverine.  Pharmacol. Toxicol. 62: 308-310."
Paricalcitol,131918-61-1,0.41,0.0016,0.89,0.9,0.0,0.86,0.86,1.04,0.96,Others,"Delgado-Herrera, Leticia; Chamberlin, Steve; Stephens, Dennis; Melnick, Joel.  Oral formulations of paricalcitol.    PCT Int. Appl.  (2005),     124 pp.  CODEN: PIXXD2  WO  2005117901. Carr RA, Andre AK, Chen P, Grabowski BA, Chang MS, Locke CS, Williams LA, and Chojkier M (2006) The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (ZemplarR).  Nephron  103: c100-c105. Graul, A.; Leeson, P. A.; Castaner, J.  Paricalcitol. Vitamin D analog. Treatment for hyperparathyroidism.    Drugs of the Future  (1998),  23(6),  602-606. http://www.rxabbott.com/pdf/zemplarivpi.pdf"
Pefloxacin,70458-92-3,1.5,0.75,2,1.9,0.1,0.90,0.95,1.03,0.92,Infection,"Frydman AM, Le Roux Y, Lefebvre MA, Djebbar F, Fourtillan JB, and Gaillot J (1986) Pharmacokinetics of perfloxacin after repeated intravenous and oral administration (400mg bid) in young healthy volunteers.  J. Antimic. Chemother.  17(Suppl B): 65-79.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet.41: 741-750."
Penciclovir,39809-25-1,1.1,0.84,8.4,1.7,6.7,0.05,0.10,0.54,0.93,Infection,"Fowles SF, Pierce DM, Prince WT, and Staniforth D (1992) The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.  Eur. J. Clin. Pharmacol. 43: 513-516.  Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV (1994) Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects.  Xenobiotica 24: 357-368."
Phencyclidine,77-10-1,6.9,0.35,5.1,4.3,0.8,0.72,0.95,0.93,0.81,nervous system,"Cook CE, Brine DR, Jeffcoat AR, Hill JM, Wall ME, Perez-Reyes M, and Di Guiseppi SR (1982) Phencyclidine disposition after intravenous and oral doses. Clin. Pharmacol. Ther. 31: 625-634. Busto U; Bendayan R; Sellers E M  Clinical pharmacokinetics of non-opiate abused drugs.    Clinical pharmacokinetics  (1989),  16(1),  1-26. "
Phenobarbital,50-06-6,0.54,0.49,0.063,0.0,0.0,1.00,1.00,1.00,1.00,nervous system,"Riva, Roberto; Albani, Fiorenzo; Contin, Manuela; Baruzzi, Agostino.  Pharmacokinetic interactions between antiepileptic drugs: Clinical considerations.    Clinical Pharmacokinetics  (1996),  31(6),  470-493Wilensky AJ, Friel PN, Levy RH, Confort CP, and Kaluzny SP (1982) Kinetics of phenobarbital in normal subjects an epileptic patients.  Eur. J. Clin. Pharmacol. 23: 87-92.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467."
Phenoxymethylpenicillin,000087-08-1,0.41,0.45,6.8,5.1,1.7,0.48,0.60,1.03,0.78,Infection,"Overbosch D, Mattie H, and van Furth R (1985) Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.  Br. J. Clin. Pharmacol.  19: 657-668.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98."
Phenytoin,57-41-0,,,0.37,0.4,0.0,0.90,0.90,1.02,0.98,nervous system,"Aquilonius S M; Hartvig P  Clinical pharmacokinetics of cholinesterase inhibitors.    Clinical pharmacokinetics  (1986),  11(3),  236-49. "
Physostigmine,57-47-6,0.66,,22,5.5,16.5,0.01,0.05,0.26,0.76,nervous system,"Aquilonius S M; Hartvig P  Clinical pharmacokinetics of cholinesterase inhibitors.    Clinical pharmacokinetics  (1986),  11(3),  236-49. "
Pindolol,13523-86-9,1.2,0.58,7.7,3.8,3.9,0.87,1.00,1.04,0.83,Cardiovascular,"Lavene D, Weiss YA, Safar ME, Loria Y, Agorus H, Georges D, and Milliez PL (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.  J. Clin. Pharmacol. 17: 501-508.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists. Br. J. Clin. pharmacol. 11: 119P-120P. "
Pirmenol,61447-94-9,1.4,0.13,1.8,1.1,0.7,0.87,0.95,0.96,0.95,Cardiovascular,"Lee T G; Goldberg A D; Chang T; Serkland M T; Yakatan G J; Johnson E L; Toole J G; Goldstein S  Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia.    Journal of cardiovascular pharmacology  (1983),  5(4),  632-7. Hammill SC, Shand DG, Routledge PA. Hindman MC, Baker JT, and Pritchett ELC (1982) Pirmenol, a new antiarrhythmic agent:  initial study of efficacy, safety and pharmacokinetics.  Circulation 65: 369-375,  "
Practolol,6673-35-4,,0.01,2,0.3,1.7,0.95,1.00,0.96,0.99,Cardiovascular,"Johnsson G; Regardh C G  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.    Clinical pharmacokinetics  (1976),  1(4),  233-63."
Pravastatin,81093-37-0,0.46,0.5,14,7.7,6.3,0.18,0.34,0.80,0.67,Cardiovascular,"Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Dispositon of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.  Br. J. Clin. Pharmacol. 29: 239-243.  Quion JA and Jones PH (1994) Clinical pharmacokinetics of pravastatin.  Clin. Pharmacokinet. 27: 94-103."
Prazosin,19216-56-9,0.73,0.06,4.7,4.5,0.2,0.68,0.86,0.98,0.80,Cardiovascular,"Kirsten, Roland; Nelson, Karen; Kirsten, Daniel; Heintz, Bernhard.  Clinical pharmacokinetics of vasodilators. Part II.    Clinical Pharmacokinetics  (1998),  35(1),  9-36. Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vanholder R, Van Landschoot N, De Smet R, Schoots A, and Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs.  Kidney Int. 33: 996-1004."
Prednisolone,50-24-8,0.86,0.25,2.9,2.3,0.6,0.75,0.99,0.84,0.90,Respiratory and inflammation,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14."
Prednisone,53-03-2,0.57,0.27,2.5,2.5,0.0,0.80,0.95,0.94,0.89,Respiratory and inflammation,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14. Georgitis JW, Flesher KA, and Szefler SJ (1982) Bioavailability assessment of a liquid prednisone preparation.  J. Allerg. Clin. Immunol. 70: 243-247.  Ferry JJ and Wagner JG (1987) The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednsolone in rabbit and human plasma.  Biopharm. Drug Dispos. 8: 261-272."
Probenecid,57-66-9,0.13,0.13,0.25,0.2,0.0,1.00,1.00,1.01,0.99,Others,"Cunningham, R. F.; Israili, Z. H.; Dayton, P. G.  Clinical pharmacokinetics of probenecid.    Clinical Pharmacokinetics  (1981),  6(2),  135-51. Kartzinel R, Ebert MH, and Chase TN (1976) Intravenous probenecid loading.  Effect on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.  Neurology 26: 992-996.  Emanuelsson BM, Beermann B, and Paalzow LK (1987) Non-linear elimination and protein binding of probenecid.  Eur. J. Clin. Pharmacol. 32: 395-401."
Procainamide,51-06-9,2.2,0.84,10,5.5,4.5,0.75,0.95,1.04,0.76,Cardiovascular,"Christoff PB, Conti DR, Naylor C, and Jusko WJ (1983) Procainamide disposition in obesity.  Drug Intell. Clin. Pharm. 17: 516-522.  Reidenberg MM, Drayer DE, Levy M, and Warner H (1975) Polymorphic acetylation of procainamide in man.  Clin. Pharmacol. Ther. 17: 722-730"
Procyclidine,77-37-2,0.74,,0.86,0.8,0.0,0.75,1.00,0.78,0.96,nervous system,"Whiteman PD, Fowle ASE, Hamilton MJ, Peck AW, Bye A, dean K, and Webster A (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man.  Eur. J. Clin. Pharmacol. 28: 73-78."
Propranolol,525-66-6,3.1,0.13,12,10.8,1.2,0.26,0.99,0.50,0.53,Cardiovascular,"Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.  Br. J. Clin. Pharmacol. 11: 119P-120P.  Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers.  Br. J. Clin. Pharmacol. 43: 563-570. Walle, T.; Walle, U. K.; Cowart, T. D.; Conradi, E. C.; Gaffney, T. E.  Selective induction of propranolol metabolism by smoking:  additional effects on renal clearance of metabolites.    Journal of Pharmacology and Experimental Therapeutics  (1987),  241(3),  928-33. "
Propylthiouracil,51-52-5,0.34,0.18,3.1,3.1,0.0,0.76,0.90,0.97,0.87,Others,"Giles HG, Roberts EA, Orrego H, and Sellers EM (1981) Disposition of intravenous propylthiouracil. J. Clin. Pharmacol. 21: 466-471. Kampmann J and Skovsted L (1974) Pharmacokinetics of propylthiouracil.  Acta Pharmacol. Toxicol. 35: 361-369.   "
Pyridostigmine,155-97-5,1.1,1,9.6,2.4,7.2,0.08,0.10,0.85,0.90,nervous system,"Aquilonius S M; Hartvig P  Clinical pharmacokinetics of cholinesterase inhibitors.    Clinical pharmacokinetics  (1986),  11(3),  236-49.  Aquilonius SM, Eckernaes SA, Hartvig P, Lindstroem B, and Osterman PO (1980) Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18: 423-428.  Kornfeld P, Samuels AJ, Wolf RL, and Osserman KE (1970) Metabolism of pyridostigmine-14C in myasthenia gravis.  Evidence for multiple metabolites.  Neurology 20: 634-641."
Quinaprilat,82768-85-2,0.13,0.32,0.93,0.0,0.9,0.50,0.61,0.82,1.00,Cardiovascular," Olson S C; Horvath A M; Michniewicz B M; Sedman A J; Colburn W A; Welling P G  The clinical pharmacokinetics of quinapril.    Angiology  (1989),  40(4 Pt 2),  351-9. Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.   Breslin E, Posvar E, Neub M, Trenk D, and Jahnchen E (1996) A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.  J. Clin. Pharmacol. 36: 414-421.  Accuretic Product Label."
Quinidine,56-54-2,2.9,0.26,4,3.4,0.6,0.75,1.00,0.88,0.85,Cardiovascular,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Fremstad D, Nilson OG, Stirsein L, Amlie J, and Jacobson S (1979) Pharmacokinetics of quinidine related to protein binding in man.  Eur. J. Clin. Pharmacol. 15: 187-192.  Woo E and Greenblatt DJ (1979) Pharmacokinetic and clinical implications of quinidine protein binding.  J. Pharm. Sci. 68: 465-469."
Quinine,130-95-0,1.8,0.3,1.9,1.6,0.3,0.76,0.80,1.02,0.93,Infection,"White NJ, Clinical pharmacokinetics of antimaliria drugs.  Clin. Pharmacokinet.  10: 187-215.  White NJ, Chanthavanich P, Krishna S, Bunch C, and Silamut K (1983) Quinine disposition kinetics.  Br. J. Clin. Pharmacol.  16: 399-403."
Rabeprazole,117976-89-3,0.22,0.037,4,4.0,0.0,0.52,0.90,0.70,0.83,Gastrointestinal/Metabolism,"Setoyama, T.; Drijfhout, W. J.; van de Merbel, N. C.; Humphries, T. J.; Hasegawa, J.  Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.    International Journal of Clinical Pharmacology and Therapeutics  (2006),  44(11),  557-565. Setoyama T, Laurent A, Humphries T, and Hasegawa J (2005) Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.  Int. J. Clin. Pharmacol. Ther. 43:  37-42."
Ranitidine,66357-35-5,1.2,0.95,9.6,2.2,7.4,0.60,0.65,1.02,0.90,Gastrointestinal/Metabolism," Van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, and De Schepper PJ (1982) Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.  Br. J. Clin. Pharmacol. 14: 195-200. Chau NP, Zech PY, Pozet N, and Hadj-Aissa A (1982) Ranitidine kinetics in normal subjects.  Clin. Pharmacol. Ther. 31: 770-774.   Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, and Schentag JJ (1984) Ranitidine disposition and systemic availability in hepatic cirrhosis.  Clin. Pharmacol. Ther. 35: 487-494."
Reboxetine,98769-81-4,0.65,0.019,0.82,0.8,0.0,0.95,1.00,0.98,0.97,nervous system,"Fleishaker JC, Mucci M, Pellizzoni C, and Poggesi I (1999) Absolute bioavailability of reboxetine enantiomers and effect of gender of pharmacokinetics.  Biopharm. Drug Dispos.  20: 53-57.  Hendershot PE, Fleishaker JC, Lin KM, Nuccio ID, and Poland RE (2001) Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents.  Psychopharmacology 155: 148-53."
Recainam,74738-24-2,1.4,0.86,4.5,2.2,2.3,0.73,0.80,1.01,0.90,Cardiovascular,"Troy S M; Cevallos W H; Conrad K A; Chiang S T; Latts J R  The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.    Journal of clinical pharmacology  (1991),  31(5),  433-9.   Anderson JL, Reddy P, Myerburg RJ, Waxman HL, and deVane PJ (1993) Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.  Am. J. Cardiol. 71: 686-694.  Scatina JA, Kimmel HB, Weinstein V, Troy SM, Sisenwine SF, and Cayen MN (1990) Species differences in the pharmacokinetics of recainam, a new antiarrythmic drug.  Biopharm. Drug Dispos. 11: 445-461."
Remoxipride,80125-14-0,0.65,0.16,1.7,1.3,0.4,0.90,1.00,0.95,0.95,nervous system,"Widman M, Nilsson LB, Bryske B, and Lundstroem J (1993) Disposition of remoxipride in different species: species differences in metabolism.  Arz. Forsch. 43: 287-297.  von Bahr C, Movin G, Yisak WA, Jostell KG, and Widman M (199) Clinical pharmacokinetics of remoxipride.  Acta Psych Scand. 358(Suppl) 41-44."
Repaglinide,135062-02-1,0.35,0.015,7.8,7.7,0.1,0.63,0.95,0.99,0.67,Gastrointestinal/Metabolism,"Hatorp V, Oliver S, and Su CAPF (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.  Int. J. Clin. Pharmacol. Ther.  36: 636-641.  Plum A, Muller LK, and Jansen JA (2000) The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.  Meth. Find. Exp. Clin. Pharmacol. 22: 139-143."
Rifabutin,72559-06-9,9.3,0.29,2.4,2.0,0.4,0.20,0.53,0.41,0.91,Infection,"Skinner M H; Blaschke T F  Clinical pharmacokinetics of rifabutin.    Clinical pharmacokinetics  (1995),  28(2),  115-25.  Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, and Blaschke TF (1989) Pharmacokinetics of rifabutin.  Antimic. Agents Chemoter. 33: 1237-1241."
Rifampin,13292-46-1,0.97,0.2,1.5,1.3,0.2,0.93,1.00,0.99,0.94,Infection,"Loos U; Musch E; Jensen J C; Mikus G; Schwabe H K; Eichelbaum M  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.    Klinische Wochenschrift  (1985),  63(23),  1205-11. Houin G, Beucler A, Richelet S, Brioude R, Lafaix C, and Tillement JP (1983) Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculosis patients after different rates of infusion.  Ther. Drug Monit. 5: 67-72."
Risedronate,105462-24-6,6.3,0.76,1.5,0.2,1.3,0.62,0.62,1.01,0.99,Gastrointestinal/Metabolism,"Mitchell DY, Barr WH, Eusebio RA, Stevens KAP, Duke FP, Russell DA, Nesbitt JD, Powell JH, and Thompson GA (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.  Pharm. Res. 18: 166-170.  Actonel Product Label."
Risperidone,106266-06-2,1.1,0.1,5.4,5.2,0.2,0.66,1.00,0.85,0.77,nervous system,"Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, and Jonkman JHG (1993)  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.  Clin. Pharmacol. Ther.  54: 257-268.  Mannens G, Meuldermans W, Snoeck E, and Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood.    Psychopharmacology 114: 566-572."
Ritonavir,155213-67-5,,,1.2,1.2,0.0,0.70,0.70,1.05,0.95,Infection,"Hsu, Ann; Granneman, G. Richard; Bertz, Richard J.  Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents.    Clinical Pharmacokinetics  (1998),  35(4),  275-291. "
Roquinimex,84088-42-6,0.21,,0.082,0.1,0.0,1.00,1.00,1.00,1.00,Cancer,"Strandgarden K, Hoglund P, Nordle O, Polacek J, Wannman H, and Gunnarsson PO.(1999) Dissolution rate-limited absorption and complete bioavailability of roquinimex in man.  Biopharm. Drug Dispos. 20: 347-354."
Rosiglitazone,122320-73-4,0.2,0.002,0.65,0.7,0.0,0.99,1.00,1.02,0.97,Gastrointestinal/Metabolism,"Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.  Drug Metab. Dispos. 28: 772-780.  Miller AK, DiCicco RA, and Freed MI (2002) The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.  Clin. Ther. 24: 1062-1071.  Avandia Product Label"
Rosuvastatin,287714-41-4,1.7,0.12,11,7.7,3.3,0.20,0.50,0.60,0.67,Cardiovascular,"Martin PD, Warwick MJ, Dane AL,  Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.  Clin. Ther. 25: 2553-2563.  Crestor Product Label."
salbutamol,18559-94-9,1.9,0.92,7.8,2.8,5.0,0.71,1.00,0.81,0.88,Respiratory and inflammation,"Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, and Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.  Br. J. Clin. Pharmacol.  22: 587-593. Boulton DW and Fawcett JP (1996) Enantioselective disposition of salbutamol in man following oral and intravenous administration.  Br. J. Clin. Pharmacol. 1996, 41, 35-40.  Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, and Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.  Br. J. Clin. Pharmacol.  22: 587-593."
Saquinavir,127779-20-8,3.6,0.028,13,12.6,0.4,0.07,0.80,0.19,0.45,Infection,"Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.  Br. J. Clin. Pharmacol. 45: 355-359.  Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.  Drug Metab. Dispos.  29: 299-303."
Scopolamine,138-12-5,3.1,,16,15.0,1.0,0.27,0.95,0.82,0.35,nervous system,"Putcha L, Cintron NM, Tsui J, Vanderploeg JM and Kramer WG (1989) Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.  Pharm. Res. 6: 481-485."
Selegiline,14611-52-0,1.9,0.13,20,19.8,0.2,0.00,1.00,0.00,0.14,nervous system,"Heinonen, EH, Anttila, MI, Lammintausta, RAS.(1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 56: 742-749.   De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004)  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet.  43: 157-185.  Emsam Product Label.  Zelapar Product Label."
Sematilide,101526-62-9,0.82,0.96,3.7,0.2,3.5,0.61,0.65,0.95,0.99,Cardiovascular,"Shi J, Ripley E, Gehr TWB, Sica DA, Dandekar KA, and Hinderling PH (1996) Pharmacokinetics of sematilide in renal failure.  J. Clin. Pharmacol. 36: 131-143.  Hinderling PH, Dilea C, Koziol T, and Millington G (1993) Comparative kinetics of sematilide in four species.  Drug Metab. Dispos. 21: 662-669."
Sildenafil,139755-83-2,1.4,0.04,9.1,9.1,0.0,0.41,0.92,0.74,0.60,Others,"Nichols DJ, Muirhead GJ, and Harness JA (2002) Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality.  Br. J. Clin. Pharmacol. 53(Suppl. 1):  5S-12S.  Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, and Wright PA (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.  Xenobiotica  29: 297-310."
Sitafloxacin,127254-12-0,1.5,0.51,3.7,0.9,2.8,0.89,0.95,0.97,0.96,Infection,"O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, and Milatovic D (2001) Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucsian subjects.  Xenobiotica 31: 811-822.  Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, and Tanaka M (1995) Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.  Antimic. Agents Chemother. 39: 170-174."
Sitagliptin,790712-60-6,2.8,0.62,6,1.3,4.7,0.89,0.95,0.99,0.95,Gastrointestinal/Metabolism,Januvia Product Label
Solifenacin,242478-38-2,8.2,0.02,2.1,2.0,0.1,0.88,1.00,0.96,0.92,nervous system,"Kuipers ME, Krauwinkel WJJ, Mulder H, and Visser N (2004) Solifenacin demonstrates high absolute bioavailability in healthy men.  Drugs R D 5: 73-81.  Krauwinkel WJJ, Smulders RA, Mulder H, Swart PJ, and Taekema-Roelvink MEJ (2005) Effect of age on the pharmacokinetics of solifenacin in men and women.  Int. J. Clin. Pharmacol. Ther. 43: 227-238."
Sotalol,3930-20-9,1.3,0.62,2,0.3,1.7,0.95,0.95,1.01,0.99,Cardiovascular,"Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, and Cheymol G (1990) The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 579-582.  Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, and Slugg PH (1997) A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37: 799-809.   Schnelle K, Klein G, and Schinz A (1979) Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J. Clin. Pharmacol. 19: 516-522.  Fiset C, Philippon F, Gilbert M, and Turgeon J (1993) Stereoselective disposition of (+/-/-)-sotalol at steady-state conditions.  Br. J. Clin. Pharmacol. 36: 75-77."
Sparfloxacin,110871-86-8,3.9,0.55,2.7,2.3,0.4,0.92,1.00,1.02,0.90,Infection,"Zagam (Sparfloxacin) tablets Rx. Hu, Peng; Zou, Qiyuan; Wang, Qinan; Zhu, Zhiben; Jiang, Yufu; Lin, Liangfang.  Pharmacokinetic study of sparfloxacin in healthy volunteers.    Zhongguo Kangshengsu Zazhi  (1999),  24(2),  152-155. Zagam Product Label. Shimada J; Nogita T; Ishibashi Y  Clinical pharmacokinetics of sparfloxacin.    Clinical pharmacokinetics  (1993),  25(5),  358-69.  "
Sufentanil,56030-54-7,9.4,0.075,15,14.9,0.1,0.00,0.90,0.00,0.35,nervous system,"Hudson RJ, Bergstrom RG, Thomson IR, Sabourin MA, Rosenbloom M, and Strunin L (1989) Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.  Anesthesiol. 70: 426-431.  Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S, Schulte am Esch J (1994) Pharmacokinetics and effects on intracranial pressure of sulfentanil in head trauma patients.  Br. J. Clin. Pharmacol. 38: 369-372.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.  Arch. Int. Pharmacodyn. Ther. 257: 4-19."
Sulfadiazine,68-35-9,0.29,0.44,0.55,0.2,0.3,0.85,0.85,1.01,0.99,Infection,"Suryawati, S.; Santoso, B.  Effect of increased doses for the renal elimination of salicylates, sulfadiazine, and sulfamethazine.    Medika  (1986),  12(1),  48-53.  Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu (1982) Coparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous administration.  J. Antimic. Chemother. 9: 461-470.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299."
Sulfamethoxazole,723-46-6,0.3,0.23,0.36,0.3,0.1,1.00,1.00,1.01,0.99,Infection,"Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299."
Sulfasalazine,599-79-1,,,0.24,0.2,0.1,0.08,0.59,0.13,0.99,Infection,"Das, K. M.; Dubin, R.  Clinical pharmacokinetics of sulfasalazine.    Clinical Pharmacokinetics  (1976),  1(6),  406-25."
Sulfinpyrazone,57-96-5,0.12,0.017,0.34,0.1,0.3,0.93,0.93,1.00,1.00,Others,"Bradbrook, I. D.; John, V. A.; Morrison, P. J.; Rogers, H. J.; Spector, R. G.  Pharmacokinetics of single doses of sulfinpyrazone and its major metabolites in plasma and urine.    British Journal of Clinical Pharmacology  (1982),  13(2),  177-85. Mahony, Cheryl; Wolfram, Katherine M.; Nash, Patricia V.; Bjornsson, Thorir D.  Kinetics and metabolism of sulfinpyrazone.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (1983),  33(4),  491-7. Lecaillion JB, Souppart C, Schoeller JP, Humbert G, and Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration.  Clin. Pharmacol. Ther. 26: 611-617.  Schlicht F, Staiger C, de Vries J, Gundert-Remy U, Hildebrandt R, Harenberg J, Wang NS, and Weber E (1985) Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.  Eur. J. Clin. Pharmacol. 28: 97-103."
Sulfisoxazole,127-69-5,0.17,0.079,0.3,0.2,0.1,0.96,1.00,0.97,0.99,Infection,"Kaplan SA, Weinfeld RE, Abruzzo CW, and Lewis M (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.  J. Pharm. Sci. 61; 773-778.  Oie S, Gambertoglio JG, and Fleckenstein L (1982) Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing.  J. Pharmacokinet. Biopharm. 10: 157-72.  Du Souich P, Calvo R, and Erill S (1990) Effects of cefotaxime on the serum protein binding of sulfisoxazole.  Biopharm. Drug Dispos. 11: 371-379."
Sulpiride,15676-16-1,2.72,0.72,1.83,0.1,1.7,0.27,0.44,0.62,0.99,nervous system,"Bres, Janine; Bressolle, Francoise.  Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations.    Journal of Pharmaceutical Sciences  (1991),  80(12),  1119-24."
Sumatriptan,103628-46-2,1.7,0.83,19,15.3,3.7,0.14,0.57,0.73,0.33,nervous system,"Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27: 337-344. Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development.  I Interspecies allometric scaling.  J. Pharmacokinet. Biopharm. 25: 149-167.  "
Suprofen,40828-46-4,0.04,0.006,0.76,0.7,0.0,0.92,0.92,1.03,0.97,Respiratory and inflammation,"Zulliger HW and Fassolt A (1985) Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. Arzneim.Forsch. 35: 976-980.  Chaikin P, Chasin M, Kennedy B, and Silverman BK (1983) Suprofen concentrations in human breast milk.  J. Clin. Pharmacol. 23: 385-390.  "
Suramin,145-63-1,0.54,0.003,0.0057,0.0,0.0,0.00,0.00,1.00,1.00,Cancer,"Collins, JM, Klecker, RW, Yarchoan, R, Lane, HC, Fauci, AS, Redfield, RR, Broder, S, Myers, CE (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 26: 22-26."
Tacrolimus,104987-11-3,1.2,0.01,0.7,0.7,0.0,0.15,0.15,1.03,0.97,Respiratory and inflammation,"Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, and Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.  Clin. Pharmacol. Ther. 69: 24-31.  Iwasaki K, Miyazaki Y, Teramura Y, Kawamura A, Tozuka Z, Hata T, and Undre N (1996) Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid.  Res. Comm. Molec. Path. Pharmacol. 94: 251-257."
Talinolol,57460-41-0,3.3,0.39,4.9,2.3,2.6,0.55,0.65,0.94,0.90,Cardiovascular,"Trausch B, Oertel R, Richter K, and Gramatte T (1995) Disposition and bioavailability of the beta1-adrenoreceptor antagonist talinolol in man.  Biopharm. Drug Dispos. 16: 403-414.  Trausch B, Oertel R, Richter K, and Gramatte T (1995) Die proteinbindung von talinolol.  Pharmazie   50: 72."
Tamsulosin,106133-20-4,0.21,0.01,0.62,0.5,0.1,1.00,1.00,1.02,0.98,Others,"van Hoogdalem E, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.  J. Pharm. Sci.  86: 1156-1161.  Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.  Drug Metab. Dispos. 26: 240-245."
Tegaserod,145158-71-0,5.3,0.02,18,17.6,0.4,0.11,0.50,0.94,0.23,Gastrointestinal/Metabolism,"Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, and Legangneux E (1999) Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.  Br. J. Clin. Pharmacol.  47: 483-491.  Appel-Dingemanse S (2002) Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity.  Clin. Pharmacokinet. 41: 1021-1042."
Telmisartan,144701-48-4,5.3,0.004,8.4,8.3,0.1,0.43,0.90,0.75,0.64,Cardiovascular,"Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PAM, van Marle SP, Tamminga WJ, Sollie FAE, and Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.  J. Clin. Pharmacol. 40: 1312-1322."
Tenoxicam,59804-37-4,0.19,0.0085,0.03,0.0,0.0,1.00,1.00,1.00,1.00,Respiratory and inflammation,"Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, and Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheum. Inflam. 7: 33-44.  Nilsen OG, Aasarod K, Wideroe TE, and Guentert TW (2001) Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.  Pharmacol. Toxicol. 89: 265-272."
Terazosin,60-87-7,0.98,0.08,1.1,1.0,0.1,0.82,0.90,0.95,0.96,Cardiovascular,Patterson SE (1985) Terazosin kinetics after oral and intravenous doses.  Clin. Pharmacol. Ther. 38: 423-427.  Sonders RC (1986) Pharmacokinetics of terazosin.  Am. J. Med. 80: 20-24.
Terbutaline,23031-25-6,1.5,0.75,3.4,1.2,2.2,0.16,0.62,0.27,0.95,Respiratory and inflammation,"Borgstrom L, Nyberg L, Jonsson S, Lindberg C, and Paulson J (1989) Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.  Br. J. Clin. Pharmacol. 27: 49-56.  Nyberg L (1984) Pharmacokinetic parameters of terbutaline in healthy man.  An overview.  Eur. J. Resp. Dis. 65(Suppl 134) 149-160.  Leferink JG, van den Berg W, Wagemaker-Engels I, Kreukniet J, and Maes RAA (1982) Pharmacokinetics of terbutaline, a beta2-sympathomimetic, in healthy volunteers and asthmatic patients.  Arz. Forsch. 32: 159-164."
Terodiline,15793-40-5,5.1,0.08,1.1,1.0,0.1,0.93,1.00,0.97,0.96,Cardiovascular,"Hallen B, Gabrielsson J, Palmer L, and Ekstrom B (1993) Pharmacokinetics of R(+/-)-terodiline given intravenously and orally to healthy volunteers.  Pharmacol. Toxicol.  73: 153-158.  Hallen B, Gabrielsson J, Nyambati S, Johansson A, Larsson E, and Guilbaud O (1995) Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.    Pharmacol. Toxicol.  76: 171-177."
Tesaglitazar,251565-85-2,0.13,0.0011,0.039,0.0,0.0,1.00,1.00,1.00,1.00,Gastrointestinal/Metabolism,"Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  Drug Metab. Dispos.  32: 923-929."
Tetracycline,60-54-8,1.2,0.78,1.5,0.6,0.9,0.77,0.90,0.88,0.97,Infection,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38:  1950-1963."
Theophylline,58-55-9,0.51,0.61,0.86,0.8,0.1,0.96,1.00,0.99,0.97,nervous system,"Kirsten, Roland; Nelson, Karen; Kirsten, Daniel; Heintz, Bernhard.  Clinical pharmacokinetics of vasodilators. Part II.    Clinical Pharmacokinetics  (1998),  35(1),  9-36.Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res.  20: 1015-1021.  Lombardi TP, Bertino JS, Goldberg A, Middleton E, and Slaughter RL (1987) The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance.    J. Clin. Pharmacol. 27: 523-529."
Tiagabine,115103-54-3,1.1,0.04,1.6,1.6,0.0,0.90,0.95,1.02,0.93,nervous system,"Jansen JA, Oliver S, Dirach J, and Mengel HB (1995)  Absolute bioavailability of tiagabine. Epilepsia  36(Suppl. 3): s159"
Tilidine,20380-58-9,4,0.21,16,15.7,0.3,0.06,1.00,0.19,0.32,nervous system,"Vollmer KO, Thomann P, and Hengy H (1989) Pharmacokinetics of tilidine and metabolites in man.  Arz. Forsch. 39: 1283-1288.  Janicke UA and Gundert-Remy U (1985) Stereoselective protein binding of (+/-)-cis and (+/-) trans tilidine.  Arch. Pharmacol. 329: R101."
Timolol,26839-75-8,1.5,0.9,8.5,7.1,1.4,0.65,0.95,0.99,0.69,nervous system,"Mantyla R; Mannisto P; Nykanen S; Koponen A; Lamminsivu U  Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.    European journal of clinical pharmacology  (1983),  24(2),  227-30.  Vermeij P, el Sherbini-Schepers M, and van Zweiten PA (1978) The disposition of timolol in man.  J. Pharm. Pharmacol. 30: 53-55.  Meier J (1982) Pharmacokinetic comparison of pindolol with other beta adrenoceptor blocking agents.  Am. Heart J. 104: 364-373."
Tinidazole,19387-91-8,0.59,0.8,0.6,0.5,0.1,1.00,1.00,1.02,0.98,Infection,"Vinge E, Andersson KE, Ando G, and Lunell E (1983) Biological availability and pharmacokinetics of tinidazole after single and repeated doses.  Scand. J. Infect. Dis.  15: 391-397.  Sawyer PR, Brogden RN, Pinder RM, Speight TM, and Avery GS (1976) Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.  Drugs 11: 423-440."
Tizanidine,51322-75-9,2.4,0.7,11,10.7,0.3,0.21,1.00,0.39,0.54,nervous system,"Zanaflex Product Label.  Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.  Br. J. Clin. Pharmacol. 57: 349-353."
Tocainide,41708-72-9,1.8,0.87,2.2,1.4,0.8,0.89,1.00,0.95,0.94,Cardiovascular,"Lalka D, Meyer MB, Duce BR, and Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.  Clin. Pharmacol. Ther. 19: 757-766.  Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, and Hillis WS (1986) The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.  Br. J. Clin. Pharmacol. 21: 149-154,  Sedman AJ, Bloedow DC, and Gal J (1982) Serum binding of tocainide and its enantiomers in human subjects.  Res. Comm. Chem Path. Pharmacol. 38: 165-168."
Tolbutamide,64-77-7,0.12,0.05,0.21,0.2,0.0,0.85,0.85,1.01,0.99,Gastrointestinal/Metabolism,"Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Ayanoglu G, Uihlein M, and Grigoleit HG (1986) A new aspect of serum protein binding of tolbutamide.  Int. J. Clin. Pharmacol. Ther. Toxicol. 24: 65-68."
Tolterodine,124937-51-5,1.5,0.037,8.4,8.4,0.0,0.26,0.77,0.53,0.63,nervous system,"Brynne N, Stahl MMS, Hallen B, Edlund PO, Palmer L, Hoglund P, and Gabrielsson J (1997) Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.  Int. J. Clin. Pharmacol. Ther. 35: 287-295.  Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine.  Clin. Pharmacol. Ther. 63: 529-539.  Pahlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species.  Biopharm. Drug Dispos. 20: 91-99."
Torsemide,56211-40-6,0.21,0.01,0.53,0.4,0.1,0.96,0.96,1.02,0.98,Cardiovascular,"Spahn, H.; Knauf, H.; Mutschler, E.  Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.    European Journal of Clinical Pharmacology  (1990),  39(4),  345-8. Spahn H, Knauf H, and Mutschler E (1990) Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.  Eur. J. Clin. Pharmacol. 39: 345-348.  Knauf H and Mutschler E (1998) Clinical pharmacokinetics and pharmacodynamics of torasemide.  Clin. Pharmacokinet. 34: 1-24."
Tramadol,27203-92-5,2.8,0.8,6.5,5.5,1.0,0.70,0.90,1.02,0.76,nervous system,"Lintz W, Barth H, Osterloh G, and Schmidt-Boethelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd communication. Suppositories.  Arz. Forsch. 48: 889-899.  Grond S and Sablotzki A (2004) Clinical pharmacology of tramadol.  Clin. Pharmacokinet. 43: 879-923."
Trazodone,19794-93-5,0.52,,1.4,1.4,0.0,0.77,1.00,0.82,0.94,nervous system,"Nilsen OG and Dale O (1992) Single dose pharmacokinetics of trazodone in healthy subjects.  Pharmacol. Toxicol. 71: 150-153. Greenblatt, David J.; Friedman, H.; Burstein, Ethan S.; Scavone, Joseph M.; Blyden, Gershwin T.; Ochs, Hermann R.; Miller, Lawrence G.; Harmatz, Jerold S.; Shader, Richard I.  Trazodone kinetics:  effect of age, gender, and obesity.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (1987),  42(2),  193-200."
Triazolam,28911-01-5,0.58,0.1,3,2.9,0.1,0.55,0.85,0.74,0.87,nervous system,"Vanderveen RP, Jirak JL, Peters GR, Cox SR, and Bombardt PA (1991) Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin. Pharm. 10: 539-543.  Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, and Juhl RP (1984) Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration.  Clin. Pharmacol. Ther. 36: 379-383. Masica, Andrew L.; Mayo, Gail; Wilkinson, Grant R.  In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (2004),  76(4),  341-349."
Trimethoprim,738-70-5,1.5,0.5,2.1,1.2,0.9,0.76,0.97,0.83,0.95,Infection,"Nissenson A R; Wilson C; Holazo A  Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis.    American journal of nephrology  (1987),  7(4),  270-4. Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu U (1982) Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion.  J. Antimic. Chemother.  9: 461-470.   Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration.  J. Pharm. Biomed. Anal. 1:  293-299."
Trovafloxacin,146836-84-2,1.3,0.24,1.4,1.3,0.1,0.88,0.95,0.98,0.95,Infection,"Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, and Friedman HL (1997) Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrovafloxacin.  J. Antimic. Chemother. 39(Suppl B): 75-80.  Teng R, Liston TE, Harris SC (1996) Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.  J. Antimic. Chemother.  37: 955-963.Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, and Friedman HL (1997) Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrovafloxacin.  J. Antimic. Chemother. 39(Suppl B): 75-80."
Urapidil,34661-75-1,0.75,,3.1,2.6,0.5,0.78,1.00,0.88,0.89,nervous system,"W. Schoetensack, E. G. Bruckschen, and K. Zech. Urapidil. New Drugs Annual: Cardiovascular Drugs, edited by Alexander Scriabine. Raven Press, New York 0 1983.Zech K, Steinijans VW, and Radtke HW (1986) Pharmacokinetics of urapidil in normal subjects. In Amery (Ed) Treatment of Hypertension with Urapidil: Preclinical and Clinical Update. 29-38, ICSS 101, RSM Services Ltd, London."
Valproic Acd,99-66-1,0.14,0.084,0.16,0.2,0.0,0.90,1.00,0.91,0.99,nervous system,"Riva, Roberto; Albani, Fiorenzo; Contin, Manuela; Baruzzi, Agostino.  Pharmacokinetic interactions between antiepileptic drugs: Clinical considerations.    Clinical Pharmacokinetics  (1996),  31(6),  470-493Bryson SM, Verma N, Scott PJW, and Rubin PC (1983) Pharmacokinetics of valproic acid in young and elderly subjects.  Br. J. Clin. Pharmacol. 16: 104-105.  Hussein Z, Patterson KJ, Lamm JE, Cavanaugh JH, and Granneman GR (1993) Effect of infusion duration on valproate pharmacokinetics.  Biopharm. Drug Dispos. 14: 389-399.  Gugler R and Meuller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.  Br. J. Clin. Pharmacol. 5: 441-446."
Valsartan,137862-53-4,0.22,0.04,0.49,0.3,0.1,0.39,0.55,0.72,0.98,Cardiovascular,"Schmidt E K; Antonin K H; Flesch G; Racine-Poon A  An interaction study with cimetidine and the new angiotensin II antagonist valsartan.    European journal of clinical pharmacology  (1998),  53(6),  451-8.Flesch G, Muller P, and Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 52: 115-120.  Colussi DM, Parisot C, Rossolino ML, Brunner LA, and Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.  J. Clin. Pharmacol. 37: 214-221."
Vancomycin,123409-00-7,0.54,0.7,1.3,0.3,1.0,0.05,0.05,1.01,0.99,Infection,"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, and Riff LJ (1988) Vancomycin pharmacokinetics in patients with various degrees of renal function.  Antimic. Agents Chemother. 32: 848-852.  Matzke GR, McGory RW, Halstenson CE, and Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimic. Agents Chemother. 25: 433-437.  Cutler NR, Narang PK, Lesko LJ, Ninos M, and Power M (1984) Vancomycin disposition: the importance of age.  Clin. Pharmacol. Ther. 36: 803-810.  Nakashima M, Katagiri K, Oguma T (1992) Phase 1 studies for vancomycin hydrochloride for injection.  Chemotherapy 40: 210-224."
Vardenafil,224785-90-4,3,0.05,13,13.0,0.0,0.15,0.90,0.37,0.43,Others,"Narang APS, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease.  Eur. J. Clin. Pharmacol. 20: 479-483.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467."
Venlafaxine,93413-69-5,4.4,0.73,14,13.4,0.6,0.42,0.97,1.03,0.42,nervous system,"Patat A, Troy S, Burke J, Trocherie S, Danjou P, LeCoz F, Allain H, and Gandon JM (1998) Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.  J. Clin. Pharmacol. 38: 256-267.  Effexor Product Label."
Verapamil,52-53-9,3.7,0.093,18,16.5,1.5,0.21,1.00,0.74,0.28,Cardiovascular," Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.   Abernethy DR, Wainer IW, Longstreth JA, and Andrawis NS (1993) Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.  J. Pharmacol. Exp. Ther. 266: 904-911.  Zachariah PK, Moyer TP, Theobald HM, Frantz RP, Kurtz SB, McCarthy JT, and Smith RL (1991) The pharmacokinetics of racemic verapamil in patients with impaired renal function.  J. Clin. Pharmacol. 31: 45-53.  Eichelbaum M, Mikus G, and Vogelgesang B (1984) Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after ntravenous administration.  Br. J. Clin. Pharmacol. 17: 453-458.  Eichelbaum M, Somogyi A, von Unruh GE, and Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isoyope-labelled verapamil.  Eur. J. Clin. Pharmacol. 19: 133-137.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  "
Vinblastine,865-21-4,28,0.14,3.1,0.5,2.6,0.05,0.05,1.02,0.98,Cancer,"Rahmani R; Samak R; Bore P; Cano J P  Clinical pharmacokinetics of vinca alkaloids.    Bulletin du cancer  (1988),  75(2),  195-200. Lu K, Yap HY, and Loo TL (1983) Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.  Canc. Res. 43: 1405-1408.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm.Res. 20: 1015-1021."
Warfarin,81-81-2,0.13,0.015,0.055,0.1,0.0,0.95,0.98,0.97,1.00,Others,"Bjornsson TD, Meffin PJ, Swezey S, and Blaschke TF (1979) Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.  J. Pharmacol. Exp. Ther. 210: 316-321. http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf"
Xamoterol,81801-12-9,0.64,0.97,3,1.1,1.9,0.05,0.05,1.05,0.95,Cardiovascular,"Bastain W, Boyce MJ, Stafford LE, Morton PB, Clarke DA, and Marlow HF (1988) Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur. J. Clin. Pharmacol. 34: 469-473.  "
Zalcitabine,7481-89-2,0.54,,5.6,1.1,4.5,0.88,1.00,0.93,0.95,Infection,"Klecker RW, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, and Myers CE (1988) Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.  J. Clin. Pharmacol. 28: 837-842. http://www.rocheusa.com/products/hivid/pi.pdf"
Zaleplon,151319-34-5,1.3,0.4,16,16.0,0.0,0.31,1.00,1.02,0.30,nervous system,"Rosen AS, Fournie P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability.  Biopharm. Drug Dispos. 20: 171-175.   Sonata Product Label. http://www.kingpharm.com/kingpharm/uploads/pdf_inserts/Sonata_PI_and_MedGuide.pdf"
Zanamivir,139110-80-8,0.23,0.86,1.6,0.2,1.4,0.03,0.11,0.28,0.99,Infection,"Cass LMR, Efthymiopoulos C, and Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.  Clin. Pharmacokinet. 36(Suppl. 1): 1-11.  Daniel MJ, Barnett JM, and Pearson BA (1999) The low potential for drug interactions with zanamivir.  Clin. Pharmacokinet. 36(Suppl. 1): 41-50. http://us.gsk.com/products/assets/us_relenza.pdf"
Ziprasidone,146939-27-7,1,0.0012,5.1,5.0,0.1,0.60,0.90,0.85,0.78,nervous system,"Miceli JJ, Wilner KD, Swan SK, and Tensfeldt TG (2005) Pharmacokinetics, safety, and tolerability of intramuscular Ziprasidone in healthy volunteers. J.Clin. Pharmacol.  45:  620-630.   Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, and Turncliff RZ (2000)  The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.  Br. J. Clin. Pharmacol. 49(Suppl 1): 27s-33s. 

"
Zolmitriptan,139264-17-8,1.8,0.75,6.7,4.5,2.2,0.39,0.92,0.53,0.80,nervous system,"Seaber EJ, Peck RW, Smith DA, Allanson J, Hefting NR, Van Lier JJm Sollie FAE, Wemer J, and Jonkman JHG (1998) The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. Clin. Pharmacol. 46: 433-439.   Dixon R and Warrander A  (1997) The clinical pharmacokinetics of zolmitriptan.  Cephalalgia 17(Suppl 18): 15-20. http://www.zomig.info/Prescribing-Information/"
Zolpidem,82626-48-0,0.54,0.08,4.3,4.3,0.0,0.72,1.00,0.88,0.81,nervous system,"Thenot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, Vajta S, Albin H, Thebault JJ, Olive G, and Warrington SJ (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and humans.  In Imidazopyridines in Sleep Disorders (ed Sauvanet JP, Langer SZ, and Morselli PL).  Raven Press, New York, pp 139-153. http://www.drugs.com/mmx/zolpidem-tartrate.html"
Zopiclone,43200-80-2,1.3,0.2,3.3,3.2,0.1,0.80,1.00,0.93,0.86,nervous system,"Gaillot J, Heusse D, Hougton GW, Marc Aurele J, Dreyfus JF (1983) Pharmacokinetics and metabolism of zopiclone.  Pharmacology 27(suppl. 2): 76-91.  Fernandez C, Gimenez F, Thuillier A, and Farinotti R (1999) Stereoselective binding of zopiclone to human plasma proteins.  Chirality 11: 129-132."
,,,,,,,,,,,,
,,,,,,,,,,,,
